Poster Presentations

POSTER PRESENTATIONS SESSION II
SET-UP:	Monday, 26 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Monday, 26 October, 8:00 – 19:00
POSTER AUTHOR DISCUSSION HOUR:	Monday, 26 October, 17:30 – 18:30
DISMANTLE:	Monday, 26 October, 19:00 – 19:30

CARDIOVASCULAR DISORDERSClinical Outcomes Studies

PCV1	MISDIAGNOSIS AND MISTREATMENT OF A COMMON SIDE-EFFECT – ACE INHIBITOR INDUCED COUGH
	Vegter S, Boersma C, De Jong-van den Berg LTW University of Groningen, Groningen, The The Netherlands

PCV2	INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS WITH UNTREATED PRIMARY HYPERPARATHYROIDISM
	Yu N, Leese GP, Donnan PT University of Dundee, Dundee, UK

PCV3	USE OF SPIRONOLACTONE IN THE TREATMENT OF CONGESTIVE HEARTH FAILURE
	Lachaine J¹, Beauchemin C², Ramos É³ ¹University of Montreal, Montréal, QC, Canada, ²University of Montreal, Montreal, QC, Canada, ³Pfizer Canada Inc, Kirkland, QC, Canada

PCV4	SIGNAL DETECTION OF BRADYCARDIA ASSOCIATED WITH ATENOLOL HYDROCHLORIDE
	Kumar A¹, Kachhadiya R² ¹Cadila Pharmaceuticals, Ahmedabad, Gujarat, India, ²VSR, Ahmedabad, Ahmedabad, Gujarat, India

PCV5	PERIODONTAL DISEASE, STATIN USE, AND CARDIOVASCULAR EVENTS
	Misra A¹, Hansen LG², Chang S¹ ¹Thomson Reuters, Washington, DC, USA, ²Thomson Reuters, Northwood, NH, USA

PCV6	DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENT RISK AMONG PRIMARY AND SECONDARY RISK DYSLIPIDEMIA MANAGED CARE PATIENTS IN THE UNITED STATES
	Balu S¹, Quimbo R², Cziraky MJ², Simko RJ¹ ¹Abbott Laboratories, Abbott Park, IL, USA, ²HealthCore, Inc., Wilmington, DE, USA

PCV7	ASSOCIATION BETWEEN DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENTS AND ASSOCIATED COST IN DYSLIPIDEMIA MANAGEMENT AMONG MANAGED CARE PATIENTS IN THE UNITED STATES
	Balu S¹, Quimbo R², Cziraky MJ², Simko RJ¹ ¹Abbott Laboratories, Abbott Park, IL, USA, ²HealthCore, Inc., Wilmington, DE, USA

PCV8	PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS WITH A MODERATE CVD RISK, WITH NO OVERT VASCULAR DISEASES NOR DIABETES MELLITUS. THE PANDORA SURVEY – BELGIUM RESULTS
	Wautrecht JC¹, Guillaume M², Thoeng J³, Matthys A⁴ ¹Erasm Hospital, Brussels, Belgium, ²CHU Charleroi, Charleroi, Belgium, ³St Elisabeth Hospital, Turnhout, Belgium, ⁴AstraZeneca Belgium, Brussels, Belgium

PCV9	CARDIOVASCULAR EVENT REDUCTION AFTER TREATMENT WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS GENERIC SIMVASTATIN THERAPY FROM A MANAGED CARE ORGANIZATION'S PERSPECTIVE IN THE UNITED STATES
	Balu S¹, Quimbo R², Simko RJ¹, Cziraky MJ² ¹Abbott Laboratories, Abbott Park, IL, USA, ²HealthCore, Inc., Wilmington, DE, USA

PCV10	A MARGINAL STRUCTURAL MODEL TO COMPARE THE EFFECTIVENESS OF INDIVIDUAL ANGIOTENSIN RECEPTOR BLOCKERS IN VETERANS WITH CHRONIC HEART FAILURE
	Johnson M¹, Desai R¹, Morgan R², Ashton CM³, Deswal A⁴, Chen H¹, Aparasu R¹ ¹University of Houston, Houston, TX, USA, ²University of Texas, Houston, TX, USA, ³Methodist Institute for Technology, Innovation, and Education, Houston, TX, USA, ⁴Baylor College of Medicine; Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

PCV11	UNDERSTANDING THE IMPACT OF STATIN TITRATION; A MODELLING APPROACH
	Gray AM¹, Thompson R², Ong S³ ¹Health Economics Research Centre, Oxford, UK, ²Pfizer, Tadworth, Surrey, UK, ³Pfizer Ltd, Tadworth, Surrey, UK

PCV12	WHAT IS THE IMPACT OF ARBS VERSUS OTHER ANTI-HYPERTENSIVES ON CV-EVENTS IN HYPERTENSIVE PATIENTS?
	Petrella RJ¹, Koa H² ¹Lawson Health Research Institute, London, ON, Canada, ²sanofi-aventis Canada, Laval, QC, Canada

PCV13	EFFECTIVENESS OF ATORVASTATIN, PRAVASTATIN AND SIMVASTATIN IN THE REDUCTION OF CARDIOVASCULAR EVENTS: AN INDIRECT COMPARISON META-ANALYSIS
	Ribeiro RA¹, Stella SF¹, Vieira JLC², Restelatto LMF³, Polanczyk CA⁴ ¹Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil, ²Instituto de Cardiologia / Fundação Universitária de Cardiologia do Rio Grande do Sul, Porto Alegre, RS, Brazil, ³Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil, ⁴Institute of Health Technology Assessment / CNPq / UFRGS, Porto Alegre, RS, Brazil

PCV14	A COMPARISON OF BLOOD PRESSURE OUTCOMES ASSOCIATED WITH THE USE OF ANGIOTENSIN-RECEPTOR BLOCKERS (ARBS) IN PATIENTS SEEN PREDOMINANTLY IN PRIMARY CARE PRACTICES
	Biskupiak J¹, Kim J² ¹University of Utah College of Pharmacy, Salt Lake City, UT, USA, ²University of Utah, Salt Lake City, UT, USA

PCV15	COMBINED OPTIMAL LIPID VALUE GOAL ATTAINMENT AFTER TREATMENT INITIATION WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS EZETIMIBE PLUS SIMVASTATIN COMBINATION THERAPY IN A MANAGED CARE PATIENT POPULATION WITH PRIOR CARDIOVASCULAR DISEASE IN THE UNITED STATES
	Balu S¹, Quimbo R², Rodgers K², Simko RJ¹, Cziraky MJ² ¹Abbott Laboratories, Abbott Park, IL, USA, ²HealthCore, Inc., Wilmington, DE, USA

PCV16	COMPARATIVE EFFICACY OF LOSARTAN AND IRBESARTAN IN HYPERTENSIVE PATIENTS AT SARABURI HOSPITAL, THAILAND 2007
	Auamnoy T¹, Lertwimonchai W¹, Chantarastapornchit V², Areepium N¹, Munprom C³ ¹Chulalongkorn University, Bangkok, Thailand, ²Silpakorn University, Nakorn Pathom, Thailand, ³Saraburi Hospital, Saraburi, Thailand

PCV17	HOW DOES THE DUAL COMBINATION OF ARBS+HCTZ COMPARE TO OTHER DUAL COMBINATIONS IN THE TREATMENT OF HYPERTENSION?
	Petrella RJ¹, Koa H² ¹Lawson Health Research Institute, London, ON, Canada, ²sanofi-aventis Canada, Laval, QC, Canada

PCV18	COST OF ACHIEVING LDL REDUCTION AMONG PATIENTS TREATED WITH EZETIMIBE CO-ADMINISTRATION COMPARED TO STATIN MONOTHERAPY IN THE UK
	Punekar YS¹, O'Regan C², Harvey P³, McCormack T⁴ ¹Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, UK, ²Merck, Sharp & Dohme Ltd., Hoddesden, UK, ³Dr Crawley & Partners, Holt, UK, ⁴Whitby Group Practice, North Yorkshire, UK

PCV19	EFFECT OF CALCIUM CHANNEL BLOCKERS ON CARDIOVASCULAR DISEASE PREVENTION
	Park HJ¹, Ko S¹, Choi W², Hwang JA³ ¹Pfizer Korea, Seoul, South Korea, ²Seoul National University College of Pharmacy, Seoul, South Korea, ³SookMyung Women's University College of Pharmacy, Seoul, South Korea

PCV20	THE EFFICACY OF CLOPIDOGREL VERSUS THE COMBINATION OF LOW DOSE ASPIRIN PLUS EXTENDED-RELEASE DIPYRIDAMOLE IN PREVENTING SERIOUS VASCULAR EVENTS: A NETWORK META-ANALYSIS
	Dewilde S¹, Eaton J², Hawkins NS³ ¹Services in Health Economics, Brussels, Belgium, ²Oxford Outcomes (UK), Oxford, Oxfordshire, UK, ³Oxford Outcomes (UK), Oxford, UK

PCV21	AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF COMBINATION THERAPIES CONTAINING ARBS VERSUS ACE INHIBITORS
	Petrella RJ¹, Charki M² ¹Lawson Health Research Institute, London, ON, Canada, ²sanofi-aventis Group, Paris, France

PCV22	CLINICAL EFFICACY OF IMPLANTABLE LOOP RECORDER IN ESTABLISHING THE CAUSES OF UNEXPLAINED OR RECURRENT SYNCOPES
	Mrozek M, Wladysiuk M, Kita K, Plisko R, Rys P HTA Consulting, Krakow, Poland

PCV23	WHAT IS THE EFFECTIVENESS OF ARBS VERSUS OTHER ANTI-HYPERTENSIVES WHEN USED AS MONOTHERAPY IN THE REAL-WORLD?
	Petrella RJ¹, Massien C² ¹Lawson Health Research Institute, London, ON, Canada, ²sanofi-aventis Group, Paris, France

PCV24	A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CLINICAL TRIALS REVIEWING ANTI-ARRHYTHMIC DRUGS FOR THE TREATMENT OF ATRIAL FIBRILLATION
	Sullivan SD¹, Orme M², Morais E³, Mitchell S² ¹University of Washington, Seattle, WA, USA, ²Abacus International, Bicester, UK, ³Sanofi Aventis, Paris, France

PCV25	THE EFFECT OF ANTI-ARRHYTHMIC DRUG THERAPY ON ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN ATRIAL FIBRILLATION PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
	Mitchell S¹, Orme M¹, Eckert L², Reynolds M³ ¹Abacus International, Bicester, UK, ²Sanofi-Aventis, Paris, France, ³Beth Israel Deaconess Medical Center, Boston, MA, USA

PCV26	PRACTICE PATTERNS AND QUALITY OF LIFE IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE NORDIC COUNTRIES: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)
	James S¹, Norrbacka K², Paget MA³, Goedicke J⁴, Tangelder M⁵, Schmitt C² ¹Akademiska Sjukhuset, Uppsala, Sweden, ²Eli Lilly and Company Ltd, Windlesham, Surrey, UK, ³Eli Lilly and Company Ltd, Suregnes, France, ⁴Eli Lilly and Company Ltd, Bad Homburg, Germany, ⁵Eli Lilly and Company Ltd, Solna, Sweden

PCV27	COUNTRY-SPECIFIC DIFFERENCES IN 12-MONTH PATTERNS OF ANTIPLATELET USE IN ACS PATIENTS UNDERGOING PCI IN 2007-08: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR)
	Zeymer U¹, Ferrieres J², Iniguez A³, Schmitt C⁴, Sartral M⁵, Belger M⁶, Bakhai A⁷ ¹Klinikum Ludwigshafen, Ludwigshafen, Germany, ²CHU Rangueil, Toulouse, France, ³Hospital Meixoeiro, Vigo, Spain, ⁴Eli Lilly and Company, Windlesham, Surrey, UK, ⁵Eli Lilly and Company Ltd, Suregnes, France, ⁶Eli Lilly and Company Ltd, Windlesham, Surrey, UK, ⁷Barnet & Chase Farm NHS Trust, Barnet, UK

PCV28	BALANCING EFFICACY AND SAFETY OF PRASUGREL VS. CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POPULATION ANALYSIS OF NET CLINICAL BENEFIT
	Schmitt C¹, McCollam PL², Creveling TL², Oberdiek A³ ¹Eli Lilly and Company, Windlesham, Surrey, UK, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Daiichi Sankyo Europe GmbH, Munich, Germany

PCV29	OUTCOMES ASSESSMENT IN LOW & HIGH RISK P.T.C.A. PATIENTS
	Singh S¹, Malhotra S², Tiwari P¹ ¹National Institute of Pharmaceutical Education & Research, Mohali, Punjab, India, ²Fortis Multispeciality Hospital, Mohali, Punjab, India

PCV30	PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008: CZECH REPUBLIC BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)
	Coufal Z¹, Norrbacka K², Hronkova M³, Paget MA⁴, Sartral M⁴, Schmitt C² ¹Bata regional Hospital, Zlin, Czech Republic, ²Eli Lilly and Company Ltd, Windlesham, Surrey, UK, ³Eli Lilly and Company Ltd, Vienna, Austria, ⁴Eli Lilly and Company Ltd, Suregnes, France

PCV31	LONGITUDINAL ASSESSMENT OF LIPID ABNORMALITIES IN A SAMPLE OF ITALIAN PATIENTS: PREVALENCE AND ATTAINMENT OF GOAL/NORMAL LEVELS
	Ambegaonkar BM¹, Heiman F², Soro M³, Sazonov V¹ ¹Merck & Co., Inc, Whitehouse Station, NJ, USA, ²Cegedim Strategic Data, Milan, Italy, ³MSD Italy, Rome, Italy

PCV32	A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID DISORDERS AMONG FRENCH PATIENTS IN PRIMARY CARE
	Laforest L¹, Ambegaonkar BM², Souchet TP³, Sazonov V², Van Ganse E⁴ ¹CHU Lyon, Bron Cedex, France, ²Merck & Co., Inc, Whitehouse Station, NJ, USA, ³Merck Sharp & Dohme - Chibret, Paris, France, ⁴CHU, Lyon, Bron Cedex, France

PCV33	ADHERENCE AND PERSISTENCE WITH STATIN THERAPY: PHARMACOUTILIZATION ANALYSIS FROM ADMINISTRATIVE DATABASES OF 5 ITALIAN LOCAL HEALTH UNITS (LHU)
	Santoni L¹, Spampinato A¹, Dall'Asta G¹, Didoni G¹, Moschetta V², Bottacchi E³, Corso G³, Bossone E⁴, Raiola V⁴, Orsini A⁵, Ruffini D⁵, Cillo M⁶ ¹Pfizer Italy, Rome, RM, Italy, ²ASL Bari, Bari, BA, Italy, ³AUSL Valle d'Aosta, Aosta, AO, Italy, ⁴ASL Salerno 1, Nocera Inferiore, SA, Italy, ⁵ASL Teramo, Teramo, TE, Italy, ⁶ASL Salerno 3, Vallo della Lucania, SA, Italy

PCV34	QUANTIFICATION METHODS OF ITALIAN PREVALENT POPULATION SUFFERING FROM ATRIAL FIBRILLATION USING PUBLISHED EPIDEMIOLOGICAL DATA
	Raviele A¹, Rudelli G² ¹Ospedale dell'Angelo, Mestre-Venice, Italy, ²sanofi-aventis S.p.A:, Milano, Italy

PCV35	PRASUGREL AND CLOPIDOGREL PERSISTENCE AND DISCONTINUATION AMONG LOWER BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES
	Zhu B¹, McCollam PL², Bae JP², Ramaswamy K³, Johnston JA², Effron MB¹ ¹Lilly USA, LLC, Indianapolis, IN, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Daiichi Sankyo Inc, Parsippany, NJ, USA

PCV36	CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART OPERATIONS UNDER THE EFFECTS OF CERTAIN HARMFUL HABITS AND OPERATIVE DATA
	Paljunite A, Kriszbacher I, Vránics I, Kovács E, Szabados S, Boncz I, Hejjel L University of Pécs, Pécs, Hungary
PCV37	PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS AT MODERATE CARDIOVASCULAR RISK – GREEK RESULTS OF THE PANDORA STUDY
	Carvounis C¹, Yourgioti G², Vaskantiras V², Nikas N² ¹“Kyanous Stavros” Medical Center, Athens, Greece, ²AstraZeneca SA, Athens, Greece

PCV38	HOSPITALIZATION AND MORTALITY IN ADVANCED-AGE PATIENTS WITH ATRIAL FIBRILLATION/ATRIAL FLUTTER BUT WITHOUT HEART FAILURE IN THE UNITED STATES
	Patel PP¹, Johnston SS², Lin J³, Schulman KL², Naccarelli GV¹ ¹Penn State University, Hershey, PA, USA, ²Thomson Reuters, Cambridge, MA, USA, ³Sanofi-Aventis, Bridgewater, NJ, USA

PCV39	RETROSPECTIVE CLAIM DATABASE ANALYSIS OF THE IMPACT OF THE ASCOT-TYPE PROFILE ON ALL-CAUSES MORTALITY AND CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS WITHOUT KNOWN CORONARY HEART DISEASE IN A MEDITERRANEAN POPULATION IN SPAIN
	Sicras A¹, Fernández de Bobadilla J², Navarro R¹, Rejas J³ ¹Badalona Servicios Asistenciales, Barcelona, Spain, ²Hospital de la Paz, Madrid, Spain, ³Pfizer Spain, Madrid, Spain

PCV40	ACUTE MYOCARDIAL AND CEREBRAL INFARCTION REGARDING TO SEASONAL, WEEKLY AND DAILY VARIATION IN CASE OF HUNGARY
	Kriszbacher I, Boncz I, Lampek K, Vas B, Mátyus A, Szalai M, Puhó-Horváth E, Zsigmond E, Bódis J University of Pécs, Pécs, Hungary

PCV41	ESTIMATION OF PERSONS ELIGIBLE FOR ICD/CRT THERAPY IN WESTERN EUROPE UNDER THE CURRENT ESC GUIDELINES: A SYSTEMATIC REVIEW OF THE LITERATURE
	Fattore G¹, Priori SG², Farah G³, Brown B³, Birinyi-Strachan L³ ¹Bocconi University, Milan, Italy, ²University of Pavia\ Fondazione "S. Maugeri, Pavia, Italy, ³Medtronic International Trading Sarl, Tolochenaz, Switzerland

PCV42	CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART OPERATIONS ACCORDING TO METEOROLOGICAL AND ASTRONOMICAL FACTORS
	Paljunite A, Hejjel L, Vránics I, Kovács E, Szabados S, Boncz I, Kriszbacher I University of Pécs, Pécs, Hungary

PCV43	USING ELECTRONIC MEDICAL RECORDS (EMRS) TO ASSESS ANTICOAGULATION STATUS ACCORDING TO STROKE RISK IN PATIENTS WITH ATRIAL FIBRILLATION IN AMBULATORY CARE SETTINGS
	Cload P¹, Marelli C², Ross S³, Zyczynski T⁴, Haas S⁵, Gunnarsson C⁶ ¹GE HealthCare LTD, Bucks, Bucks, England, ²GE HealthCare LTD, Bucks, Giles Bucks, England, ³SDRoss Consulting, Cohasset, MA, USA, ⁴GE Healthcare, Princeton, NJ, USA, ⁵s2 Statistical Solutions, Inc., Cincinnati, OH, USA, ⁶S2 Statistical Solutions, Inc, Cincinnati, OH, USA

PCV44	HEART FAILURE IN OLDER PEOPLE: A STUDY OF FACTORS THAT LEAD TO HOSPITALISATION
	Brown SH, Abdelhafiz AH Rotherham General Hospital, Rotherham, UK

PCV45	DETERMINING A MODEL-DERIVED RELATIVE STROKE RISK THRESHOLD TO JUSTIFY CAROTID STENTING IN SURGICAL HIGH-RISK PATIENTS
	Smolen HJ¹, Klein RW¹, Klein TM¹, Cohen DJ² ¹Medical Decision Modeling Inc, Indianapolis, IN, USA, ²Saint Luke's Mid America Heart Institute, Kansas City, MO, USA

PCV46	PERFLUTREN PROTEIN-TYPE A MICROSPHERES INJECTABLE SUSPENSION, USP DOES NOT INCREASE MORTALITY IN CRITICALLY ILL PATIENTS: RESULTS FROM A RETROSPECTIVE PROPENSITY-MATCHED CASE-CONTROL STUDY
	Main M¹, Exuzides A², Colby C², Feinstein S³, Goldman J⁴, Waaler A⁵, Grayburn P⁶ ¹Saint Luke's Mid America Heart Institute, Kansas City, MO, USA, ²ICON Clinical Research, San Francisco, CA, USA, ³Rush Presbyterian Medical Center, Chicago, IL, USA, ⁴ICON Medical Imaging, San Francisco, CA, USA, ⁵GE Healthcare, Horten, Norway, ⁶Baylor University Medical Center, Dallas, TX, USA

PCV47	THE QUANTIFICATION OF THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) AND ALL-CAUSE MORTALITY
	Simons WR¹, Edwards DM² ¹Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, ²Abbott Australasia, Botany, NSW, Australia

CARDIOVASCULAR DISORDERSCost Studies

PCV48	A GERMAN HOSPITAL BUDGET IMPACT MODEL COMPARING ANTICOAGULATION STRATEGIES IN PERCUTANEOUS CORONARY INTERVENTION
	Olchanski N¹, Slawsky K¹, Fusfeld L¹, Cyr PL¹, Schwenkglenks M², Möckel M³, Zeymer U⁴ ¹Boston Healthcare Associates, Inc., Boston, MA, USA, ²University of Basel, Basel, Switzerland, ³Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Herzzentrum Ludwigshafen, Ludwigshafen, Germany

PCV49	FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A GERMAN HEALTH CARE PAYER PERSPECTIVE
	Hadker N¹, Garg S¹, Costanzo C¹, Miller JD¹, van der Helm W², Foster T¹, Creeden J² ¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Roche Diagnostics, Ltd, Rotkreuz, Switzerland

PCV50	BUDGET IMPACT OF BIVALIRUDIN IN STEMI PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PPCI) IN UK HOSPITALS
	Olchanski N¹, Slawsky K¹, Cyr PL¹, Schwenkglenks M², Kinnaird T³ ¹Boston Healthcare Associates, Inc., Boston, MA, USA, ²University of Basel, Basel, Switzerland, ³University Hospital of Wales, Cardiff, UK

PCV51	THE POTENTIAL ECONOMIC IMPACT OF RECONFIGURING TIA CARE IN ITALY
	Jackson D¹, Moshinsky J², Begg A² ¹GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK, ²Medaxial Group, London, UK

PCV52	RECONFIGURING TIA CARE PATHWAYS IN HUNGARY: AVOIDING RECURRENT STROKE
	Jackson D¹, Moshinsky J², Begg A² ¹GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK, ²Medaxial Group, London, UK

PCV53	FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A UK HEALTH CARE PAYER PERSPECTIVE
	Hadker N¹, Garg S¹, Costanzo C¹, Miller JD¹, van der Helm W², Foster T¹, Creeden J² ¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Roche Diagnostics, Ltd, Rotkreuz, Switzerland

PCV54	EXAMINING THE COST IMPACTS OF RECONFIGURING TIA CARE IN SPAIN
	Jackson D¹, Moshinsky J², Begg A² ¹GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK, ²Medaxial Group, London, UK

PCV55	BUDGET IMPACT ANALYSIS OF DIAGNOSTIC OF UNEXPLAINED AND/OR RECURRENT SYNCOPE WITH APPLICATION OF IMPLANTABLE LOOP RECORDER
	Gwiosda B, Palka I, Karas D, Wladysiuk M, Szmurlo D, Rutkowski J, Plisko R, Rys P HTA Consulting, Krakow, Poland

PCV56	IMPACT OF INCLUDING PRASUGREL ON THE FORMULARY FOR PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME
	Mauskopf J¹, Graham JB¹, Bae JP², Gaich C² ¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PCV57	COSTS OF ATRIAL FIBRILLATION IN SLOVAKIA FROM A PAYER PERSPECTIVE
	Bielik J¹, Tomek D², Visnansky M³, Foltan V⁴, Lednar M⁵ ¹Trencin University, Trencin, Slovak Republic, ²Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, ³General Health Insurance Company, Bratislava, Slovak Republic, ⁴Comenius University, Bratislava, Slovak Republic, ⁵sanofi-aventis Pharma Slovakia, s.r.o., Bratislava, Slovak Republic

PCV58	THE DIAGNOSTIC BENEFIT OF STRESS TEST PRIOR TO CARDIAC MULTI-SLICE COMPUTED TOMOGRAPHY IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE: CLINIC AND ECONOMIC OUTCOMES FROM THE EMILIA-ROMAGNA MSCT REGISTRY
	Berti E, Cipriani F, Negro A, Marino M, De Palma R Emilia Romagna Social & Healthcare Agency, Bologna, Italy

PCV59	COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF BETA BLOCKERS FOR CHRONIC HEART FAILURE PATIENTS IN SPAIN
	Espallardo O, Polanco C Merck, Madrid, Spain

PCV60	BUDGET IMPACT MODEL FOR DETERMINING THE HOSPITAL COSTS OF INTRODUCING PRASUGREL FOR THE LONG TERM TREATMENT OF ACUTE CORONARY SYNDROME TREATED BY PERCUTANEOUS CORONARY INTERVENTION IN FRANCE
	Chevreul K¹, Granados D², Wang K³, Vainchtock A⁴, Tcherny-Lessenot S², McCollam PL⁵, Schmitt C⁶, Mahoney EM³ ¹Henri Mondor Hospital, URC Health Economics, Creteil, Paris, France, ²Lilly France, Suresnes, France, ³Saint Luke's Mid America Heart Institute, Kansas City, MO, USA, ⁴HEVA, Lyon, France, ⁵Eli Lilly and Company, Indianapolis, IN, USA, ⁶Eli Lilly and Company, Windlesham, Surrey, UK

PCV61	COST OF EXERCISE TRAINING AND ITS IMPACT ON MEDICAL RESOURCE USE AND COSTS: RESULTS OF HF-ACTION TRIAL
	Reed SD¹, Whellan DJ², Li Y¹, Friedman JY¹, Pina IL³, Settles SJ¹, Davidson-Ray L⁴, Johnson J¹, Cooper LS⁵, O'Connor CM¹, Schulman KA¹ ¹Duke Clinical Research Institute, Durham, NC, USA, ²Thomas Jefferson University, Philadelphia, PA, USA, ³Case Western Reserve University School of Medicine, Cleveland, OH, USA, ⁴Duke University, Durham, NC, USA, ⁵National Heart Lung and Blood Institute, Bethesda, MD, USA

PCV62	PULMONARY ARTERIAL HYPERTENSION (PAH) COST OF ILLNESS IN THE U.S. PRIVATELY-INSURED POPULATION
	Kirson NY¹, Birnbaum HG¹, Ivanova JI², Schiller M¹, Waldman T¹, Williamson T³ ¹Analysis Group, Inc., Boston, MA, USA, ²Analysis Group, Inc., New York, NY, USA, ³Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA

PCV63	COST OF CARDIOVASCULAR DISEASE IN KOREA: INCIDENCE-BASED APPROACH
	Lee YS¹, Kim BJ², Rha SW³, Ham GR¹, Seo HS¹, Moon OR⁴ ¹PrimeCore Consulting, Seoul, South Korea, ²Kangbuk-Samsung Medical Center, Seoul, South Korea, ³Korea University Guro Hospital, Seoul, South Korea, ⁴Inje Graduate School of Public Health, Seoul, South Korea

PCV64	SHORT AND LONG-TERM ECONOMIC BURDEN OF ISCHEMIC STROKE/TIA PATIENTS
	Berenson K, Malangone E, Stern L, Casciano R Analytica International, New York, NY, USA

PCV65	TWO-YEAR CLINICAL AND ECONOMIC IMPACT OF PERIPHERAL ARTERIAL DISEASE ON PATIENTS FROM SPAIN WITH ESTABLISHED CORONARY ARTERY OR CEREBROVASCULAR DISEASE: RESULTS FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY
	Ramirez de Arellano A¹, Suarez-Fernandez C², Betegón L³, Wang K⁴, Mahoney EM⁴ ¹Bristol-Myers Squibb Iberia, Madrid, Spain, ²Hospital La Princesa, Madrid, Spain, ³Sanofi-Aventis, Madrid, Spain, ⁴Saint Luke's Mid America Heart Institute, Kansas City, MO, USA

PCV66	COST BURDEN OF ATHENA ENDPOINTS IN ATHENA-LIKE PATIENTS WITH ATRIAL FIBRILLATION/ATRIAL FLUTTER BUT WITHOUT HEART FAILURE IN THE UNITED STATES
	Patel PP¹, Naccarelli GV¹, Johnston SS², Lin J³, Schulman KL² ¹Penn State University, Hershey, PA, USA, ²Thomson Reuters, Cambridge, MA, USA, ³Sanofi-Aventis, Bridgewater, NJ, USA

PCV67	A COST-OF-ILLNESS ANALYSIS OF ATRIAL FIBRILLATION IN SWEDEN
	Ericson L¹, Bergfeldt L², Björholt I¹ ¹Nordic Health Economic Research AB, Gothenburg, Sweden, ²Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

PCV68	CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) COST OF ILLNESS IN THE PRIVATELY-INSURED POPULATION IN THE UNITED STATES
	Kirson NY¹, Birnbaum HG¹, Ivanova JI², Schiller M¹, Waldman T¹, Williamson T³ ¹Analysis Group, Inc., Boston, MA, USA, ²Analysis Group, Inc., New York, NY, USA, ³Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA

PCV69	THE COST-OF-ILLNESS OF ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW
	Wolowacz SE¹, Samuel M¹, Brennan VK¹, Jasso-Mosqueda JG², Van Gelder IC³ ¹RTI-Health Solutions, Manchester, UK, ²Sanofi-Aventis, Paris, France, ³University Medical Center Groningen, Gronigen, The The Netherlands

PCV70	MANAGEMENT OF ACUTE ISCHEMIC STROKE (IS) AND ASSOCIATED COSTS OVER A 12-MONTH PERIOD IN FRANCE
	Saragoussi D¹, Guilhaume C², Dorey J³, Toumi M⁴ ¹Lundbeck company, paris, France, ²Lundbeck SAS, Paris, France, ³Creativ-Ceutical, Paris, France, ⁴University Claude Bernard Lyon I, Villeurbanne Cedex, France

PCV71	PREVALENCE AND ECONOMIC BURDEN OF HYPERTENSION IN PATIENTS WITH METABOLIC SYNDROME IN SPAIN: AN EPIDEMIOLOGICAL COST-OF-ILLNESS MODEL
	Alegría E¹, Piñol C², Langham S³, Stevens W⁴, Jeffries D⁵ ¹Clinica Universitaria de Navarra, Pamplona, Navarra, Spain, ²Bayer HealthCare, Barcelona, Spain, ³Independent Consultant, Manchester, UK, ⁴Independent Consultant, Boston, MA, USA, ⁵MRC Tropical Disease Research Unit, Banjul, Gambia

PCV72	ESTIMATING LIFETIME ECONOMIC BURDEN OF STROKE IN KOREA ACCORDING TO THE AGE OF ONSET: USING NATIONAL HEALTH INSURANCE CLAIMS DATABASE
	Kang HY¹, Lim SJ¹, Chang HS¹, Liew D² ¹Yonsei University, Seoul, South Korea, ²The University of Melbourne, Melbourne, Victoria, Australia

PCV73	COST–ANALYSIS OF STROKE PATIENTS WITH THE INTEGRATED WESTERN AND ORIENTAL MEDICAL TREATMENT IN SOUTH KOREA
	Ku MJ¹, Lee EK² ¹SookMyung Women's University, seoul, seoul, South Korea, ²Sook Myung Women's University, Seoul, South Korea

PCV74	INCREMENTAL COSTS OF HYPERTENSION, HYPERGLYCEMIA, HYPERLIPIDEMIA, AND THEIR COMBINATIONS
	Tang CH¹, You SL², Sun CA³, Bai CH⁴, Pwu RF⁵, Hung ST¹ ¹Taipei Medical University, Taipei, Taiwan, ²Academia Sinica, Taipei, Taiwan, ³Fu Jen Catholic University, Taipei, Taiwan, ⁴Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, ⁵Center for Drug Evaluation, Taipei, Taiwan
PCV75	PATIENTS WITH PULMONARY EMBOLISM AFTER ORTHOPAEDIC SURGERY HAVE SIGNIFICANTLY INCREASED COSTS FOR INPATIENT STAY
	Lukac M¹, Bielik J², Foltán V³, Tomek D⁴, Zatko D⁵ ¹Faculty of Public Health at Slovak Medical University, Bratislava, Slovak Republic, ²Trencin University, Trencin, Slovak Republic, ³Comenius University, Bratislava, Slovak Republic, ⁴Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, ⁵General Health Insurance, Bratislava, Slovak Republic

PCV76	DIRECT COSTS OF DIAGNOSTIC AND TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN GERMANY
	Benkert D¹, Wasem J², Aidelsburger P¹ ¹CAREM GmbH, Sauerlach, Germany, ²University of Duisburg-Essen, Essen, Germany

PCV77	HEALTH CARE COSTS AND RESOURCE UTILIZATION FOR ACUTE CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS
	Zhao Z¹, Zhu B², Anderson J¹, Bayt T², LeNarz L² ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Lilly USA, LLC, Indianapolis, IN, USA

PCV78	ONE-YEAR HEALTH CARE COSTS FOR ACUTE CORONARY SYNDROME PATIENTS WITH DIFFERENT TREATMENT STRATEGIES DURING THE INITIAL HOSPITALIZATION
	Zhao Z, Winget M Eli Lilly and Company, Indianapolis, IN, USA

PCV79	BURDEN OF ILLNESS STUDY IN PATIENTS WITH RESISTANT HYPERTENSION IN UK
	Wasiak R¹, Kreif N¹, Stull D¹, Tyas DA² ¹United BioSource--Europe, London, UK, ²Novartis Pharmaceuticals UK Ltd, Camberley, Surrey, UK

PCV80	LONGITUDINAL COST IMPACT OF ATRIAL FIBRILLATION IN PATIENTS SUFFERING FROM CARDIOVASCULAR DISEASES
	Reinhold T¹, Hessel F², Willich SN¹, Brüggenjürgen B¹ ¹Charite University Medical Center, Berlin, Germany, ²Sanofi-Aventis, Berlin, Germany

PCV81	ECONOMIC IMPLICATIONS OF OBESITY AMONG PEOPLE WITH ATHEROTHROMBOTIC DISEASE IN AUSTRALIA
	Ademi Z¹, Walls H¹, Peeters A¹, Hollingsworth B¹, Liew D², Bhatt D³, Steg G⁴, Reid C¹ ¹Monash University, Melbourne, Australia, ²The University of Melbourne, Melbourne, Victoria, Australia, ³Harvard University, Boston , MA, USA, ⁴Université Paris VII, Paris, France

PCV82	THE IMPACT OF LOST THERAPEUTIC BENEFIT (LTB) IN HIGH RISK PATIENTS MANAGED FOR HYPERTENSION IN AUSTRALIAN GENERAL PRACTICE
	Huq MM¹, Magliano D², Liew D³, Owen A⁴, Bhatt D⁵, Steg G⁶, Reid C¹ ¹Monash University, Melbourne, Australia, ²Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, ³The University of Melbourne, Melbourne, Australia, ⁴Monash University, Melbourne, Victoria, Australia, ⁵Harvard University, Boston , MA, USA, ⁶Université Paris VII, Paris, France

PCV83	RELATIONSHIP BETWEEN THE COST AND HOSPITAL QUALITY
	Baser O University of Michigan and STATinMED Research, Ann Arbor, MI, USA

PCV84	AN ASSESSMENT OF THE COST OF PERCUTANEOUS PULMONARY VALVE IMPLANTATION USING MELODY VERSUS SURGICAL VALVE REPLACEMENT IN PATIENTS WITH RIGHT VENTRICULAR OUTFLOW TRACT DYSFUNCTION
	Raikou M¹, McGuire A¹, Lurz P², Bonhoeffer P², Wegmueller Y³ ¹London School of Economics and Political Science, London, UK, ²Great Ormond Street Hospital, London, UK, ³Medtronic Trading Sarl, Geneva, Switzerland

PCV85	COST CONSEQUENCES OF REDUCED CVD RISK THROUGH IMPROVED SBP CONTROL: A COMPARATIVE ANALYSIS OF VALSARTAN VERSUS LOSARTAN
	Baker TM¹, Goh J¹, Dastani HB², Brede Y³, Falvey H³, Getsios D⁴ ¹United BioSource Inc., Bethesda, MD, USA, ²Novartis Pharmaceuticals Corp, East Hanover, NJ, USA, ³Novartis Pharma AG, Basel, Switzerland, ⁴United BioSource Corporation, Lexington, MA, USA

PCV86	COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN HIGH-RISK PATIENTS WITH SYMPTOMATIC AORTIC VALVE STENOSIS IN FRANCE
	Fagnani F¹, Litzler PY², Eltchaninoff H², Cribier A², Banz K³ ¹Cemka-Eval, Bourg-La-Reine, France, ²CHU Charles Nicolle, Rouen, France, ³Outcomes International, Basel, Switzerland

PCV87	COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND PLANNED PCI: RESULTS FROM THE TRITON-TIMI 38 TRIAL FROM THE GERMAN PERSPECTIVE
	Mahoney EM¹, Wang K¹, McCollam PL², Schmitt C³, Cohen DJ¹ ¹Saint Luke's Mid America Heart Institute, Kansas City, MO, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Eli Lilly and Company, Windlesham, Surrey, UK

PCV88	THE COST EFFECTIVENESS OF AMBRISENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN IRELAND
	Redmond S¹, Bozkaya D² ¹GlaxoSmithKline, Dublin 16, Ireland, ²United BioSource Corporation, Concord, MA, USA

PCV89	PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FROM THE PERSPECTIVE OF THE UNITED KINGDOM NATIONAL HEALTH SERVICE? A MODEL-BASED ANALYSIS
	Davies A¹, Sculpher M², Schmitt C³, Barrett A⁴, Baird J⁵, Zanotti G⁶, Bakhai A⁷ ¹Oxford Outcomes (UK), Oxford, England, ²University of York, York, UK, ³Eli Lilly and Company, Windlesham, Surrey, UK, ⁴Eli Lilly and Company Ltd, Windlesham, Surrey, UK, ⁵Eli Lilly and Company Limited, Basingstoke, UK, ⁶Eli Lilly and Company, Windlesham, UK, ⁷Barnet & Chase Farm NHS Trust, Barnet, UK

PCV90	PATIENTS ADMITTED TO THE ICU AFTER CARDIOPULMONARY RESUSCITATION: AN ANALYSIS OF OUTCOME, QUALITY OF LIFE AND COST-EFFECTIVENESS
	Oeyen S¹, Vandijck D², Vandenbossche J¹, Benoit D¹, Annemans L², Colardyn F¹, Decruyenaere J¹ ¹Ghent University Hospital, Ghent, Belgium, ²Ghent University, Ghent, Belgium

PCV91	COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN AS ADJUNCTIVE THERAPY WITH FIBRINOLYSIS IN SPANISH PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI): RESULTS FROM EXTRACT-TIMI 25.
	Betegón L¹, Weintraub W², Zhang Z² ¹Sanofi-Aventis, Madrid, Spain, ²Christiana Care Health System, Newark, DE, USA

PCV92	COST-EFFECTIVENESS OF AN EXERCISE TRAINING PROGRAM IN HEART FAILURE
	Kuhr EM, Ribeiro RA, Rohde LE, Beck da Silva LN, Clausell NO, Ribeiro JP, Polanczyk CA Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

PCV93	COST-EFFECTIVENESS ANALYSIS OF EZETIMIBE/SIMVASTATIN COMPARED WITH DOUBLING THE STATIN DOSE: ANALYSIS OF THE INFORCE STUDY IN THE UNITED KINGDOM
	Reckless JP¹, Davies GM², Tunceli K³, Hu XH⁴, Brudi P⁵ ¹Royal United Hospital, Bath, UK, ²Merck Research Laboratories, West Point, PA, USA, ³Merck & Co., Inc., Whitehouse Station, NJ, USA, ⁴Merck & Co., Inc, Whitehouse Station, NJ, USA, ⁵Merck/Schering-Plough Cholesterol Partnership, Whitehouse Station, NJ, USA

PCV94	THE COST-EFFECTIVENESS OF TITRATION TO GOAL WITH BRAND ROSUVASTATIN COMPARED TO GENERIC SIMVASTATIN IN PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL: PRIMARY AND SECONDARY PREVENTION IN THE BELGIAN HEALTH CARE SETTING
	Van den Steen D¹, Petit C², Lamotte M¹ ¹IMS Health, Brussels, Belgium, ²NV AstraZeneca SA, Brussels, Belgium

PCV95	COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES IN SOUTH KOREA
	Shin S¹, Yang BM¹, Kim Y² ¹Seoul National University, Seoul, South Korea, ²Sanofi aventis Korea, Seoul, South Korea

PCV96	COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN CHRONIC STABLE ANGINA PATIENTS IN A FINNISH SETTING
	Félix J¹, Almeida J¹, Joutseno J², Alegre P³ ¹Exigo Consultores, Alhos Vedros, Lisbon, Portugal, ²Servier Finland OY, Vantaa, Finland, ³Servier, Suresnes , France

PCV97	COST-EFFECTIVENESS OF IVABRADINE IN PATIENTS WITH CHRONIC STABLE ANGINA IN A DUTCH SETTING
	Almeida J¹, Félix J¹, Renkens M², Alegre P³ ¹Exigo Consultores, Alhos Vedros, Lisbon, Portugal, ²Servier Nederland Farma BV, Leiden, CC Leiden, The The Netherlands, ³Servier, SURESNES , France

PCV98	COST-EFFECTIVENESS OF ORGANISED INPATIENT CARE FOR STROKE
	Launois R¹, Garrigues B², Maunoury F³, Riou França L⁴ ¹REES France, Paris, Paris, France, ²Centre Hospitalier du Pays d'Aix, Aix en Provence, Bouches-du-Rhône, France, ³STATESIA, Le Mans, France, ⁴REES France, Paris, PAris, France

PCV99	PHARMACOECONOMICS OF DIRECT RENIN INGIBITOR ALISKIREN IN HYPERTENSION TREATMENT OF PATIENTS WITH TYPE-2 DIABETES AND NEPHROPATHY
	Rudakova AV Military Medical Academy, St-Petersburg, Russia

PCV100	THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), NICOTINIC ACID AND ALL-CAUSE MORTALITY
	Simons WR¹, Edwards DM² ¹Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, ²Abbott Australasia, Botany, NSW, Australia

PCV101	IS PRASUGREL COST-EFFECTIVE RELATIVE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FROM THE PERSPECTIVE OF THE GERMAN HEALTH CARE SYSTEM? A MODEL-BASED ANALYSIS
	Davies A¹, Sculpher M², Schmitt C³, Barrett A⁴, Clouth J⁵, McCollam PL⁶, Bakhai A⁷ ¹Oxford Outcomes (UK), Oxford, England, ²University of York, York, UK, ³Eli Lilly and Company, Windlesham, Surrey, UK, ⁴Eli Lilly and Company Ltd, Windlesham, Surrey, UK, ⁵Lilly Deutschland GmbH, Bad Homburg, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, USA, ⁷Barnet & Chase Farm NHS Trust, Barnet, UK

PCV102	COST-EFFECTIVENESS OF VARIOUS ‘SCREEN-AND-TREAT' SCENARIOS DIRECTED AT ELEVATED ALBUMINURIA TO PREVENT CARDIOVASCULAR AND RENAL DISEASE IN THE GENERAL POPULATION
	Boersma C¹, Gansevoort RT², Pechlivanoglou P¹, Visser ST¹, de Jong-van den Berg LTW¹, de Jong PE², Postma MJ¹ ¹University of Groningen, Groningen, The The Netherlands, ²University Medical Center Groningen, Groningen, The The Netherlands

PCV103	COST-EFFECTIVENESS OF EXTENDED VERSUS NON-EXTENDED PROPHYLAXIS WITH ENOXAPARIN IN HIGH-RISK SURGICAL PATIENTS IN AUSTRALIA
	Tilden D¹, Lee JM² ¹THEMA Consulting Pty Ltd, Sydney, Australia, ²Sanofi-Aventis Australia Pty Ltd, Macquarie Park, NSW, Australia

PCV104	THE COST-EFFECTIVENESS ANALYSIS IN SCREENING OF DEEP VEIN THROMBOSIS IN A CLINICAL LABORATORY
	Bogavac-Stanojevic N¹, Dopsaj V¹, Vasic D², Jelic-Ivanovic Z¹ ¹University in Belgrade, Belgrade, Serbia, Serbia and Montenegro, ²Clinical Centre of Serbia, Belgrade, Serbia, Serbia and Montenegro

PCV105	COST-EFFECTIVENESS OF GENEOTYPE-GUIDED DOSING OF SHORT -TERM USE OF WARFARIN AMONG DVT/PE PATIENTS
	Teschemaker AR¹, Lawrence W² ¹Howard University, Washington, DC, USA, ²Agency for Healthcare Research and Quality, Rockville, MD, USA

PCV106	PREDICTED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE OPTIMAL LIPID VALUES WHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH A STATIN IN SPECIAL PATIENT POPULATIONS WITH MIXED DYSLIPIDEMIA
	Webb SF¹, Sorensen SV², Williamson R³ ¹Abbott Laboratories, Abbott Park, IL, USA, ²United BioSource Corporation, Bethesda, MD, USA, ³UnitedBiosource Corporation, Bethesda, MD, USA

PCV107	ECONOMIC EVALUATION OF EZETIMIBE COMBINED WITH SIMVASTATIN FOR TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA
	Van Nooten F¹, Davies GM², Jukema JW³, Liem AH⁴, Hu XH⁵ ¹United BioSource Corporation, London, UK, ²Merck and Co, Blue Bell, PA, USA, ³Leiden University Medical Center, Leiden, The The Netherlands, ⁴Oosterscheldeziekenhuizen, Goes, The The Netherlands, ⁵Merck & Co., Inc, West Point, PA, USA
PCV108	COST EFFECTIVENESS OF MPLANTABLE LOOP RECORDERS (ILRS) FOR UNEXPLAINED SYNCOPE DIAGNOSTICS IN FRANCE
	Debroucker F, Graciet A Medtronic France, Boulogne Billancourt Cedex, France

PCV109	COST EFFECTIVENESS OF STATIN THERAPY IN SOUTH KOREA
	Bae EY¹, Bae S², Lim MK³, Choi SE⁴ ¹Sangji University, Gangwondo, South Korea, ²Health Insurance Review and Assessment Service, Seoul, South Korea, ³Health Insurance Review Agency, Seoul, Seocho-Gu, South Korea, ⁴Seoul National University, Seoul, South Korea

PCV110	COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY
	Weitz J¹, Bernard L², Wakeford C³ ¹McMaster University, Hamilton, ON, Canada, ²Cornerstone Research Group, Burlington, ON, Canada, ³Sanofi-Aventis, Laval, QC, Canada

PCV111	A PATIENT'S VIEW OF THE COST-EFFECTIVENESS OF USING LOW-DOSE ASPIRIN FOR CVD (CARDIOVASCULAR DISEASE) PRIMARY PREVENTION IN MIDDLE-AGED MEN IN THE UK
	Amirsadri-Naeini M, Jackson PR University of Sheffield, Sheffield, South Yorkshire, UK

PCV112	COST EFFECTIVENESS OF RIVAROXABAN AND DABIGATRAN ETEXILATE FOR THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AND ASSOCIATED LONG TERM COMPLICATIONS POST TOTAL HIP REPLACEMENT IN IRELAND
	McCullagh L¹, Tilson L¹, Walsh C², Barry M¹ ¹National Centre for Pharmacoeconomics, Dublin, Ireland, ²Trinity College Dublin, Dublin, Ireland
PCV113	COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN IN EXTENDED PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN MAJOR ORTHOPEDIC SURGERY IN POLAND
	Kawalec P¹, Kuzma J¹, Glogowski C², Krzyzanowska A³ ¹Centrum HTA, Krakow, Poland, ²GSK Commercial Sp. z o.o, Warsaw, Poland, ³GlaxoSmithKline Poland, Warsaw, Poland
PCV114	DABIGATRAN ETEXILATE IS COST-SAVING FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING MAJOR ORTHOPAEDIC SURGERY IN THE NETHERLANDS
	Boersma C¹, Kappelhoff BS², Postma MJ¹ ¹University of Groningen, Groningen, The The Netherlands, ²Boehringer Ingelheim bv, Alkmaar, The The Netherlands

PCV115	TIROFIBAN IS MORE COST-EFFICIENT THAN ABCIXIMAB IN ACHIEVING ST-SEGMENT RESOLUTION FOLLOWING ACUTE MYOCARDIAL INFARCTION
	DeMaria J¹, Wong B², Valgimigli M³ ¹Iroko Pharmaceuticals, Philadelphia, PA, USA, ²Bruce Wong & Associates Inc., Radnor, PA, USA, ³Azienda Opedaliera Universitaria di Ferrara, Ferrara, Italy

PCV116	COST-EFFECTIVENESS OF BIVALIRUDIN VERSUS HEPARIN PLUS GLYCOPROTEIN IIB/IIIA INHIBITOR IN THE TREATMENT OF ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION – A HORIZONS TRIAL ANALYSIS USING UK VALUATIONS
	Schwenkglenks M¹, Szucs TD¹, Brazier JE², Blackman DJ³, Cyr P⁴, Olchanski N⁴, Stone GW⁵ ¹University of Basel, Basel, Switzerland, ²University of Sheffield, Sheffield, UK, ³Leeds General Infirmary, Leeds, UK, ⁴Boston Healthcare Associates, Inc, Boston, MA, USA, ⁵Columbia University Medical Center, New York, NY, USA

PCV117	COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND – A DISCRETE EVENT SIMULATION MODELLING
	Soini EJ¹, Stevenson MD², Martikainen JA³, Akehurst RL² ¹ESiOR Oy, Kuopio, Finland, ²University of Sheffield, Sheffield, UK, ³ESiOR Oy and Department of Social Pharmacy, University of Kuopio, Kuopio, Finland

PCV118	ECONOMIC EVALUATION OF INHALED ILOPROST IN PRIMARY PULMONARY HYPERTENSION IN THE UK
	Ashley D¹, Lloyd AC², Gilmour L¹ ¹Bayer Healthcare Pharmaceuticals Inc, Newbury, UK, ²IMS Health, London, UK
PCV119	COST-EFFECTIVENESS OF ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE NETHERLANDS
	Thurston SJ¹, Webb K², Ong S², Meerding WJ³, van Hout BA¹ ¹Pharmerit Ltd, York, North Yorkshire, UK, ²Pfizer Ltd, Tadworth, Surrey, UK, ³Pfizer bv, Capelle a/d IJssel, The The Netherlands

PCV120	DRONEDARONE IN ATRIAL FIBRILLATION: MODELING HEALTH OUTCOMES
	Åkerborg Ö¹, Bascle S², Lindgren P¹ ¹i3 Innovus, Stockholm, Sweden, ²Sanofi-Aventis, Paris, France

PCV121	ENDOVASCULAR TREATMENT FOR ACUTE ISCHEMIC STROKE IN THE NETHERLANDS. A COST-UTILITY ANALYSIS
	Bouvy J, Koopmanschap M, Niessen L, Dippel DW Erasmus MC, Rotterdam, The The Netherlands

PCV122	ANGIOGRAPHY FOR DIAGNOSING PAOD: COST COMPARISON OF THE DIAGNOSTIC PROCEDURES MRA AND DSA
	Bergmann K¹, Lungershausen J², Schwenke C³ ¹Bayer Schering Pharma, Berlin, Germany, ²IMS HEALTH (At the time of this research topic), Nuremberg, Germany, ³SCO:SSiS, Berlin, Germany

PCV123	COST OF ARTERIAL HYPERTENSION ACCORDING TO LEVELS OF MORBIDITY IN PRIMARY CARE SETTING
	Sicras-Mainar A¹, Navarro-Artieda R², Rejas J³ ¹Badalona Serveis Assistencials SA, Barcelona, Spain, ²Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, ³Pfizer Spain, Madrid, Spain

PCV124	COST OF CORONARY ARTERY BYPASS GRAFT (CABG) IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC
	Ondrackova B¹, Miklik R², Parenica J², Spinar J², Sulcova A¹, Tomcikova D¹ ¹Masaryk University, Brno, Czech Republic, ²University Hospital Brno, Brno, Czech Republic

PCV125	EVALUATION OF THE ASSOCIATION BETWEEN SERUM SODIUM AND LENGTH OF STAY (LOS) IN PATIENTS HOSPITALIZED FOR HEART FAILURE
	Cyr PL¹, Slawsky K¹, Olchanski N¹, Krasa H², Zimmer C², Ouyang J², Goss TF³, Udelson J⁴, Hauptman PL⁵ ¹Boston Healthcare Associates, Inc., Boston, MA, USA, ²Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA, ³Boston Healthcare Associates, Inc., Washington, DC, USA, ⁴Tufts Medical Center, Boston, MA, USA, ⁵Saint Louis University School of Medicine, Saint Louis, MO, USA

PCV126	REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIA
	Mahoney EM¹, Wang K¹, Bae JP², Zhu B², Marciniak MD², Effron MB², Cohen DJ¹ ¹Saint Luke's Mid America Heart Institute, Kansas City, MO, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PCV127	EFFECT OF TOLVAPTAN ON HOSPITAL LENGTH OF STAY (LOS) WITHIN HYPONATREMIC PATIENTS HOSPITALIZED FOR HEART FAILURE
	Cyr PL¹, Slawsky K¹, Olchanski N¹, Krasa H², Zimmer C², Ouyang J², Goss TF³, Udelson J⁴, Hauptman PL⁵ ¹Boston Healthcare Associates, Inc., Boston, MA, USA, ²Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA, ³Boston Healthcare Associates, Inc., Washington, DC, USA, ⁴Tufts Medical Center, Boston, MA, USA, ⁵Saint Louis University School of Medicine, Saint Louis, MO, USA

PCV128	LOADING WITH WARFARIN PROLONGS LENGTH OF HOSPITAL STAY IN PATIENTS WITH ATRIAL FIBRILLATION
	Tan ES, Brown SH, Bonnett TJ, Abdelhafiz AH Rotherham General Hospital, Rotherham, UK

CARDIOVASCULAR DISORDERSPatient-Reported Outcomes Studies
PCV129	METHODOLOGY TO ASSESS THE IMPACT OF POOR COMPLIANCE WITH COMMON TREATMENTS
	Meszaros A, Truman P University of York, York, UK

PCV130	COMPLIANCE (ADHERENCE) TO ANTIHYPERTENSIVE THERAPY IN AUSTRALIA
	Ortiz M¹, Calcino G² ¹Solvay Pharmaceuticals Australia, Pymble, NSW, Australia, ²Hi Connections Pty Ltd, Woden, ACT, Australia

PCV131	NONADHERENCE AND DISCONTINUATION OF LOW-DOSE ACETYLSALICYLIC ACID IN PATIENTS WITH CARDIOVASCULAR RISK: THE IMPACT OF GASTROINTESTINAL SYMPTOMS
	Sörstadius E¹, Thompson VJ², Pratt SE³, Delgado JP⁴, Elkin E⁵, Nauclér E¹, Næsdal J¹, Junghard O¹ ¹AstraZeneca R&D, Mölndal, Sweden, ²Libra Clinical Research Associates LLC, Brick, NJ, USA, ³Harmony Clinical Research, San Ramon, CA, USA, ⁴Integrated Medical Research, Ashland, OR, USA, ⁵ICON Clinical Research, San Francisco, CA, USA

PCV132	DIFFERENCES IN PERSISTENCE BETWEEN CCBS WHEN COMBINED WITH AN A2RA OR AN ACE ANTIHYPERTENSIVE IN AUSTRALIA

	Ortiz M¹, Calcino G² ¹Solvay Pharmaceuticals Australia, Pymble, NSW, Australia, ²Hi Connections Pty Ltd, Woden, ACT, Australia

PCV133	INFLUENCING FACTORS TO A GOOD ADHERENCE IN PATIENTS WITH CHRONIC HEART DISEASES
	Origasa H, Sugiura S, Kumagai N, Sumi S University of Toyama School of Medicine, Toyama, Japan

PCV134	PREDICTORS OF NON-PERSISTENCE ON STATIN TREATMENTS IN ITALY: A RETROSPECTIVE
	Cammarota S¹, De Portu S², Riegler S³, Citarella A¹, Menditto E¹, Mantovani LG³ ¹University of Naples, Naples, Italy, ²University Federico II, Naples, Italy, ³University of Naples, Federico II, Naples, Italy

PCV135	HEALTH STATUS IN AN ARGENTINIAN POPULATION SURVEY : RESULTS FROM THE NATIONAL RISK FACTOR SURVEY
	Augustovski FA¹, Irazola V¹, Kind P² ¹Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina, ²University of York, York, UK

PCV136	HEALTH STATE UTILITY VALUES FOR ATRIAL FIBRILLATION AND ASSOCIATED TREATMENT-RELATED ADVERSE EVENTS
	Doyle S¹, Lloyd A², Craig AM³ ¹Oxford Outcomes, Oxford, Oxon, UK, ²Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, ³Sanofi Aventis, Guildford, Surrey, UK

PCV137	WITHDRAWN


PCV138	COMPARATIVE RESEARCH BETWEEN ORAL AND SUBCUTANEOUS THROMBOPROPHYLAXIS: THE STOPWATCH PROJECT
	Quante M¹, Thate-Waschke IM² ¹Klinikum Neustadt GmbH & Co. Betriebs-KG, Neustadt in Holstein, Greece, ²Bayer Vital GmbH, Leverkusen, NRW, Germany

PCV139	PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS: A UK PILOT STUDY OF ATRIAL FIBRILLATION PATIENTS RECEIVING WARFARIN
	Robinson P¹, Cottrell S², Tilden D², LeReun C³ ¹Boehringer Ingelheim Ltd, Bracknell, UK, ²THEMA Consulting Pty Ltd, Sydney, Australia, ³Independent Statistician, Carrigaline, Ireland

PCV140	PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS: A UK PILOT STUDY OF WARFARIN-NAÏVE ATRIAL FIBRILLATION PATIENTS
	Cottrell S¹, LeReun C², Tilden D¹, Robinson P³ ¹THEMA Consulting Pty Ltd, Sydney, Australia, ²Independent Statistician, Carrigaline, Ireland, ³Boehringer Ingelheim Ltd, Bracknell, UK

PCV141	UPPER GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH CARDIOVASCULAR RISK TAKING LOW-DOSE ACETYLSALICYLIC ACID: AN OBSERVATIONAL STUDY
	Sörstadius E¹, Thompson VJ², Pratt SE³, Delgado JP⁴, Elkin E⁵, Nauclér E¹, Næsdal J¹, Junghard O¹ ¹AstraZeneca R&D, Mölndal, Sweden, ²Libra Clinical Research Associates LLC, Brick, NJ, USA, ³Harmony Clinical Research, San Ramon, CA, USA, ⁴Integrated Medical Research, Ashland, OR, USA, ⁵ICON Clinical Research, San Francisco, CA, USA
PCV142	ASSESSING THE QUALITY OF QUALITY OF LIFE MEASURES IN HEART FAILURE: A COMPARISON OF AVAILABLE INSTRUMENTS
	Herdman M¹, Garin O¹, Vilagut G¹, Ribera A², Permanyer-Miralda G², Ferrer M³, Rajmil L⁴, Valderas JM⁵, Alonso J³ ¹CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Cataluña, Spain, ²Hospital Vall d'Hebrón, Barcelona, Cataluña, Spain, ³Institut Municipal d'Investigació Mèdica, Barcelona, Cataluña, Spain, ⁴Catalan Agency for Health Technology Assessment and Research, Barcelona, Cataluña, Spain, ⁵University of Manchester, Manchester, UK

PCV143	EXPLORING PATIENTS' SATISFACTION WITH ANTICOAGULANT TREATMENT BY APPLYING STRUCTURAL EQUATION MODELS TO THE PERCEPTION OF ANTICOAGULANT TREATMENT QUESTIONNAIRE (PACT-Q)
	Regnault A¹, Gilet H¹, Carita P², Arnould B³ ¹Mapi Values France, Lyon, France, ²Sanofi Aventis R&D, Paris, France, ³Mapi Values, Lyon, France
PCV144	HEALTH-RELATED QUALITY OF LIFE AND RESOURCE USE IN PATIENTS WITH METABOLIC SYNDROME: A COMPARISON OF THE UNITED STATES, EUROPE, AND JAPAN
	Wagner S¹, Fukuda T², Nagae T³, Gupta S¹, DiBonaventura M¹, Stankus AP¹ ¹Consumer Health Sciences International, Princeton, NJ, USA, ²University of Tokyo, Bunkyo, Tokyo, Japan, ³York Pharma KK, Tokyo, Japan
PCV145	IMPACT OF HOSPITALIZATION ON HEALTH-RELATED QUALITY OF LIFE IN ATRIAL FIBRILLATION PATIENTS
	Reynolds MR¹, Hui G², Zimetbaum P¹ ¹Beth Israel Deaconess Medical Center, Boston, MA, USA, ²Harvard Clinical Research Institute, Boston, MA, USA
PCV146	HAS THE TYPE OF ATRIAL FIBRILLATION DIFFERENT IMPACT ON HRQOL?
	Arribas F¹, Ormaetxe JM², Peinado R³, Fernandez C⁴, Ramírez P⁴, Badia X⁵ ¹Hospital 12 de Octubre, Madrid, Spain, ²Hospital de Basurto, Bilbao, Spain, ³Hospital La Paz, Madrid, Spain, ⁴MEDA Pharma, Madrid, Spain, ⁵IMS Health, Barcelona, Spain

PCV147	EXPERIENCE WITH UPPER GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH CARDIOVASCULAR RISK TREATED WITH LOW-DOSE ACETYLSALICYLIC ACID
	Sörstadius E¹, Thompson VJ², Pratt SE³, Delgado JP⁴, Nauclér E¹, Næsdal J¹, Junghard O⁵ ¹AstraZeneca R&D, Mölndal, Sweden, ²Libra Clinical Research Associates LLC, Brick, NJ, USA, ³Harmony Clinical Research, San Ramon, CA, USA, ⁴Integrated Medical Research, Ashland, OR, USA, ⁵AstraZeneca R&D, Mölndal, Göteberg, Sweden
PCV148	HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERCHOLESTEROLEMIA
	Müller-Nordhorn J¹, Englert H², Wegscheider K³, Berger H⁴, Völler H⁵, Katus HA⁶, Willich SN¹ ¹Charité University Medical Center, Berlin, Germany, ²University of Applied Sciences, Münster, Germany, ³Department of Medical Biometry and Epidemiology, Hamburg, Germany, ⁴University of Applied Sciences, Osnabrück, Germany, ⁵Klinik am See, Rüdersdorf, Germany, ⁶Department of Cardiology, Heidelberg, Germany

PCV149	ASSESSMENT OF QUALITY OF LIFE AMONG PATIENTS WITH HYPERTENSION AND DIABETES TYPE 2
	Turska W, Skowron A Jagiellonian University Collegium Medicum, Cracow, Poland

PCV150	WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH METABOLIC SYNDROME: A COMPARISON OF THE UNITED STATES, EUROPE, AND JAPAN
	Wagner S¹, Fukuda T², Nagae T³, Gupta S¹, DiBonaventura M¹, Stankus AP¹ ¹Consumer Health Sciences International, Princeton, NJ, USA, ²University of Tokyo, Bunkyo, Tokyo, Japan, ³York Pharma KK, Tokyo, Japan

CARDIOVASCULAR DISORDERSHealth Care Use & Policy Studies
PCV151	WITHDRAWN

PCV152	ASSESSING THE IMPACT OF A COMMUNITY PHARMACY BASED MTM PROGRAM ON OUTCOMES FOR EMPLOYEES WITH HYPERTENSION
	Pinto SL, Bechtol R, Partha G The University of Toledo, Toledo, OH, USA

PCV153	MARYLAND MEN'S CARDIOVASCULAR PROMOTION – MVP
	Shaya FT¹, Ke X¹, Yan X¹, Norman N¹, Shematek J² ¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²CareFirst BlueCross BlueShield, Owings Mills, MD, USA

PCV154	THE INFLUENCE OF INSURANCE COMPANIES' REGULATIONS ON DRUG UTILIZATION; THE EXAMPLE OF SIMVASTATIN AND PREFERENCE POLICY
	Pechlivanoglou P, Postma MJ, Wieringa J University of Groningen, Groningen, The The Netherlands

PCV155	IMPACT OF EXPANDING PHARMACY BENEFITS ON TREATMENT OF CONGESTIVE HEART FAILURE: THE CASE OF MEDICARE PART D
	Donohue JM¹, Zhang Y¹, Lave J¹, Gellad WF², Perera S¹, Men A¹, Hanlon J¹ ¹University of Pittsburgh, Pittsburgh, PA, USA, ²RAND, Pittsburgh, PA, USA

PCV156	WITHDRAWN


PCV157	MEDICATION ADHERENCE AND PERSISTENCE OF CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS WITH AND WITHOUT DIABETES MELLITUS
	Zhu B¹, Zhao Z², Bayt T¹, Bae JP², McCollam PL², Anderson J², LeNarz L¹ ¹Lilly USA, LLC, Indianapolis, IN, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PCV158	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM: USAGE IN CROATIA DURING A SEVEN-YEAR PERIOD
	Vitezic D¹, Matana Kastelan Z², Buble T³, Vitezic M⁴, Kovacevic M⁵, Mrsic Pelcic J⁶, Zupan G⁶ ¹University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia, ²University Hospital Centre Rijeka, Rijeka, Croatia, ³Croatian National Health Insurance, Zagreb, Croatia, ⁴University Hospital for Orthopedic Surgery Lovran, Lovran, Croatia, ⁵University Hospital Centre Rijeka and University of Rijeka School of Medicine, Rijeka, Croatia, ⁶University of Rijeka Medical School, Rijeka, Croatia

PCV159	WITHDRAWN


PCV160	REAL-WORLD PRACTICE PATTERNS OF ACUTE CORONARY SYNDROME (ACS) PATIENTS WITH AND WITHOUT DIABETES MELLITUS (DM)
	Zhao Z¹, Zhu B², Anderson J¹, Bayt T², LeNarz L² ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Lilly USA, LLC, Indianapolis, IN, USA

PCV161	HEALTHCARE RESOURCES UTILIZATION IN ACUTE CORONARY SYNDROME PATIENTS ONE YEAR AFTER PCI : FRENCH RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY (APTOR)
	Ferrieres J¹, Tcherny S², Granados D², Sartral M³ ¹CHU Rangueil, Toulouse, France, ²Lilly France, Suresnes, France, ³Eli Lilly and Company Ltd, Suregnes, France

PCV162	PUBLIC TENDERING FOR OFF PATENT PHARMACEUTICALS IN BELGIUM – THE SIMVASTATIN CASE
	VanHaeren E, Arickx F, Soete E, Bormans V, Mortier M, Leveque F RIZIV-INAMI National Health Insurance Agency, Brussels, Belgium

PCV163	GENDER-BASED DIFFERENCES IN HEALTH CARE COSTS AMONG ACS PATIENTS: AN APPLICATION OF THE BLINDER-OAXACA DECOMPOSITION
	Zhao Z, Winget M Eli Lilly and Company, Indianapolis, IN, USA

PCV164	PRESSURES FACED BY PEOPLE WHO CARE FOR SOMEBODY DIAGNOSED WITH A CARDIOVASCULAR CONDITION
	Hutton J, Beale S, Kruger J York Health Economics Consortium, York, UK

PCV165	CHANGES IN THE COST-EFFICACY OF STATINS IN SPAIN AFTER THE INTRODUCTION OF GENERICS AND REFERENCE PRICES
	Plans-Rubió P General Directorate of Public Health, Barcelona, Spain

PCV166	ADENOSINE-STRESS CARDIAC MAGNETIC RESONANCE IMAGING IN SUSPECTED CORONARY ARTERY DISEASE: A NET COST ANALYSIS & REIMBURSEMENT IMPLICATIONS
	Pilz G¹, Patel PA², Fell U³, Rizzo JA⁴, Fang H⁵, Gunnarsson C⁶, Graw M¹, Hoefling B¹ ¹Clinic Agatharied, University of Munich, Hausham, Germany, ²GE Healthcare, Barrington, IL, USA, ³GE Healthcare, Munich, Germany, ⁴Stony Brook University, Stony Brook, NY, USA, ⁵University of Colorado, Aurora, CO, USA, ⁶S2 Statistical Solutions, Inc, Cincinnati, OH, USA
PCV167	A CLUSTER RANDOMIZED CONTROLLED TRIAL TO EVALUATE AN AMBULATORY PRIMARY CARE MANAGEMENT PROGRAM FOR PATIENTS WITH DYSLIPIDEMIA: TEAM STUDY
	Lalonde L¹, Villeneuve J¹, Genest J², Blais L¹, Vanier MC¹, Lamarre D¹, Fredette M³, Perreault S¹, Hudon E⁴, Djamal B⁵ ¹University of Montreal, Montreal, QC, Canada, ²McGill University Health Center, Royal-Victoria Hospital, Montreal, QC, Canada, ³HEC, Montreal, QC, Canada, ⁴Centre de Santé et Services Sociaux de Laval, Laval, QC, Canada, ⁵Centre de santé et de services sociaux de Laval, Laval, QC, Canada

PCV168	COMMUNITY PHARMACY DISPENSING OF PRESCRIPTION MEDICINE SAMPLE PACKS – CHANGING THE BUSINESS OF MEDICINE INITIATION?
	Kyle GJ, Nissen LM, Tett SE The University of Queensland, St Lucia, QLD, Australia

PCV169	ACETYLSALICYLIC ACID(ASA) MONOTHERAPY FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: AN ASSESSMENT OF THE MEDICAL BENEFIT USING THE IQWIG METHODOLOGICAL APPROACH
	Maxion-Bergemann S¹, Hessel F², Dietrich ES¹ ¹HealthEcon AG, Basel, Europe, Switzerland, ²Sanofi-Aventis, Berlin, Germany
PCV170	A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID DISORDERS AMONG HUNGARIAN PATIENTS IN PRIMARY CARE
	Kiss Z¹, Erdesz D², Nagy L², Mark L³, Blaho G¹, Sazonov V⁴, Ambegaonkar BM⁴ ¹Merck Sharp & Dohme Hungary, Budapest, Hungary, ²Merck Sharpe & Dohme, Budapest, Hungary, ³Pándy Ferenc Hospital, Gyula, Hungary, ⁴Merck & Co., Inc, Whitehouse Station, NJ, USA

PCV171	CRITICAL APPRAISAL OF THE JAPANESE GUIDELINE FOR THE MANAGEMENT OF STROKE
	Origasa H University of Toyama, Toyama, Japan

PCV172	TREATMENT PATTERNS AMONG PATIENTS WITH HYPERTENSION: RESULTS OF A US SURVEY
	Sun SX¹, Annunziata K², Xu Y¹, Bolge SC², Leahy M¹ ¹Global Health Economics and Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, ²Consumer Health Sciences International, Princeton, NJ, USA

POSTER PRESENTATIONS SESSION II
SET-UP:	Monday, 26 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Monday, 26 October, 8:00 – 19:00
POSTER AUTHOR DISCUSSION HOUR:	Monday, 26 October, 17:30 – 18:30
DISMANTLE:	Monday, 26 October, 19:00 – 19:30

GASTROINTESTINAL DISORDERS Clinical Outcomes Studies
PGI1	A RECORD-LINKAGE STUDY OF ADVERSE UPPER GASTRO-INTESTINAL EVENTS WITH NSAIDS IN A UK POPULATION UTILISING DIFFERENT EPIDEMIOLOGICAL DESIGNS TO MINIMISE CONFOUNDING
	Donnan PT University of Dundee, Dundee, Scotland, UK

PGI2	WORK PRODUCTIVITY IN PRIMARY CARE PATIENTS CONSULTING WITH COMPLAINTS OF UPPER GASTROINTESTINAL SYMPTOMS: ESTIMATES FROM THE DANISH RESPONSE STUDY
	Malmberg I¹, Meineche-Schmidt V², Christensen E³, Bytzer P⁴ ¹AstraZeneca, Albertslund, Denmark, ²Copenhagen University, Copenhagen, Denmark, ³Bispebjerg Hospital, Copenhagen, Denmark, ⁴Køge University Hospital, Køge, Denmark

PGI3	INTRAVENOUS (IV) PROTON PUMP INHIBITORS (PPIS) FOR THE TREATMENT OF PEPTIC ULCER BLEEDING (PUB)
	Edwards SJ, Gray J, Borrill J AstraZeneca UK Ltd, Luton, UK

PGI4	SYSTEMATIC REVIEW: THE CLINICAL EFFECTIVENESS OF ANTI-TNF-ALPHA DRUGS IN ADULTS WITH REFRACTORY CROHN'S DISEASE
	Assasi N¹, Blackhouse G¹, Xie F¹, Marshall JK¹, Irvine J², Gaebel K¹, Robertson D¹, Campbell K¹, Hopkins R¹, Goeree R¹ ¹McMaster University, Hamilton, ON, Canada, ²St Michael's Hospital, Toronto, ON, ON, Canada

PGI5	PREDICTORS FOR RESPONSE TO PRUCALOPRIDE IN PATIENTS WITH CHRONIC CONSTIPATION
	Dubois D¹, Kerstens R², Vandeplassche L², Wouters L³ ¹PVS Consultancy, Huldenberg, Belgium, ²Movetis, Turnhout, Belgium, ³I-Biostat, Hasselt University, Diepenbeek, Belgium

GASTROINTESTINAL DISORDERS Cost Studies
PGI6	EVALUATION OF RESOURCE UTILIZATION AND ECONOMIC IMPACT OF RECURRENCE FOR INGUINAL HERNIA REPAIR PERFORMED WITH PHS DEVICE VERSUS POLYPROPYLENE MESH UNDER THE BRAZILIAN PRIVATE PAYER PERSPECTIVE
	Baran R, Pontes DAR, Negri MA Johnson & Johnson Medical Brasil, Sao Paulo, SP, Brazil

PGI7	MANAGEMENT OF OPIOID INDUCED CONSTIPATION (OIC) IN PAIN PATIENTS: A COST OF ILLNESS STUDY IN BELGIUM AND THE NETHERLANDS
	Caekelbergh K¹, Lamotte M², Van Megen Y³ ¹IMS Health Economics and Outcomes Research (HEOR), Brussels, Belgium, ²IMS Health, Brussels, Belgium, ³Mundipharma Pharmaceuticals BV, MV Hoevelaken, The The Netherlands

PGI8	COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS PROTON PUMP INHIBITORS (IV PPI) FOR THE PREVENTION OF GASTRIC OR DUODENAL ULCER REBLEEDING AFTER THERAPEUTIC ENDOSCOPY
	Borrill J, Edwards SJ, Gray J AstraZeneca UK Ltd, Luton, UK

PGI9	COST-EFFECTIVENESS OF INTRAVENOUS IRON IN INFLAMMATORY BOWEL DISEASE PATIENTS INTOLERANT TO ORAL IRON
	Borg S¹, Glenngård AH¹, Danielson BG², Persson U¹ ¹The Swedish Institute for Health Economics (IHE), Lund, Sweden, ²University Hospital, Uppsala, Sweden

PGI10	ECONOMIC EVALUATION OF A MULTIDISCIPLINARY SUPPORT PROGRAM IN HEPATITIS C TREATMENT: PRELIMINARY RESULTS
	Martín-Escudero V¹, García-Retortillo M², Giménez MD², Cirera I², Márquez C², Castellví P², Navinés R³, Urbina O⁴, Salas E⁴, Martín-Santos R³, Varela C¹, Solà R² ¹Roche Farma, Madrid, Spain, ²Liver Section, Hospital del Mar, IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain, ³Psychiatric Service/Pharmacology Unit of Investigation, Hospital del Mar, IMIM, Barcelona, Spain, ⁴Pharmacy Service, Hospital del Mar, IMIM, Barcelona, Spain

PGI11	THE COST EFFECTIVENESS OF INFLIXIMAB IN THE TREATMENT OF ACUTE ULCERATIVE COLITIS PATIENTS IN SCOTLAND
	Shore E Schering-Plough, Welwyn Garden City, Herts, England

PGI12	RESOURCE UTILIZATION AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS C (CHC) IN THAILAND: A HEAVY BUT MANAGEABLE ECONOMIC BURDEN
	Thongsawat S¹, Piratvisuth T², Pramoolsinsap C³, Chutaputti A⁴, Tanwandee T⁵, Sukarom I⁶, Tinmanee S⁶ ¹Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand, ²Songklanagarind Hospital, Prince of Songkla University, Songkla, Thailand, ³Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁴Phramongkutklao Hospital, Bangkok, Thailand, ⁵Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁶Roche Thailand Ltd, Bangkok, Thailand

PGI13	WITHDRAWN

PGI14	WITHDRAWN

PGI15	TREATMENT OF MODERATE TO SEVERE PAIN WITH OXYCODONE/NALOXONE TO REDUCE OPIOID-INDUCED CONSTIPATION: A COST-UTILITY ANALYSIS IN BELGIUM AND THE NETHERLANDS
	Gerlier L¹, Lamotte M¹, Van Megen Y² ¹IMS Health, Brussels, Belgium, ²Mundipharma Pharmaceuticals BV, MV Hoevelaken, The The Netherlands

PGI16	RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH OPIOID-INDUCED CONSTIPATION (OIC) IN CANCER PATIENTS IN SWEDEN
	Ovanfors A¹, Kasteng F², Borgstrom F², Iyer S³ ¹Wyeth Pharmaceuticals, Solna, Sweden, ²i3 Innovus, Stockholm, Sweden, ³Wyeth Research, Collegeville, PA, USA

PGI17	CONSUMPTION OF HEALTHCARE RESOURCES ASSOCIATED WITH CURRENT MANAGEMENT STRATEGIES FOR NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: AN OBSERVATIONAL EUROPEAN STUDY
	Lanas A¹, Tafalla M², Nuevo J² ¹1Service of Digestive Diseases, University Hospital, IACS, CIBERehd, Zaragoza, Spain, ²AstraZeneca, Madrid, Spain


GASTROINTESTINAL DISORDERS Patient-Reported Outcomes Studies
PGI18	EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON GENERIC HEALTH RELATED QUALITY OF LIFE USING THE EQ-5D INDEX SCORES IN PATIENTS WITH CHRONIC NON-MALIGNANT PAIN AND OPIOID-INDUCED CONSTIPATION
	Iyer S, Randazzo B, Tzanis E, Schulman S, Zhang H, Wang W, Manley A Wyeth Research, Collegeville, PA, USA

PGI19	PATIENT RELEVANT ASPECTS OF DIAGNOSTIC QUESTIONNAIRES AND THEIR SUBSCALES IN GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD)
	Burkowitz J¹, Gross M², Beckenbauer U³, Brueggenjuergen B⁴ ¹Alpha Care GmbH, Celle, Germany, ²Internistische Klinik Dr. Müller, Munich, Germany, ³H-M-O Health Management Online AG, Oberhaching, Germany, ⁴Steinbeis Business Academy, Berlin, Germany

PGI20	EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON PATIENT REPORTED CONSTIPATION SPECIFIC QUALITY OF LIFE IN A RANDOMIZED DOUBLE –BLIND CLINICAL TRIAL
	Iyer S, Randazzo B, Tzanis E, Schulman S, Zhang H, Wang W, Manley A Wyeth Research, Collegeville, PA, USA

WP4	DISCRETE CHOICE EXPERIMENT TO DETERMINE WILLINGNESS-TO-PAY FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) TREATMENT
	Ciobanu A¹, Marshall DA², Deal K³, Bukoski M¹, Dabrowski D⁴
	¹AstraZeneca, Mississauga, ON, Canada, ²University of Calgary, Calgary, AB, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴I3 Innovus, Burlington, ON, Canada

GASTROINTESTINAL DISORDERSHealth Care Use & Policy Studies
PGI21	TREATMENT OF CHRONIC HEPATITIS C WHICH DO NOT FOLLOW CLINICAL GUIDELINES IS INCREASING DIRECT MEDICAL COSTS
	Lukac M¹, Bielik J², Zatko D³ ¹Faculty of Public Health at Slovak Medical University, Bratislava, Slovak Republic, ²Trencin University, Trencin, Slovak Republic, ³General Health Insurance, Bratislava, Slovak Republic

PGI22	CIRCULAR STAPLED HAEMORRHOIDOPEXY IN THE TREATMENT OF HAEMORRHOIDAL PROLAPSE: HTA REPORT - LOMBARDIA REGION, ITALY
	Berto P¹, Boccasanta P², Bordoni L³, Lenisa L⁴, Lopatriello S¹, Schivazappa C¹ ¹PBE Consulting, Verona, Italy, ²Fondazione IRCCS Ospedale Policlinico Mangiagalli e Regina Elena, Milano, Italy, ³Ospedale di Circolo e Fondazione Macchi, Varese, Italy, ⁴Casa di Cura S. Pio X, Milano, Italy

PGI23	STAPLED HAEMORRHOIDOPEXY IN THE TREATMENT OF HAEMORRHOIDAL PROLAPSE – COMPARISON OF HTA REPORTS, FOR TWO ITALIAN REGIONS
	Berto P¹, Lopatriello S¹, Schivazappa C¹, Benvenuti F², Boccasanta P³, Bordoni L⁴, Lenisa L⁵, Naldini G⁶, Nepi S², Todaro A⁷, Valeri A⁷ ¹PBE Consulting, Verona, Italy, ²Ospedale Valdelsa, Poggibonsi, Italy, ³Fondazione IRCCS Ospedale Policlinico Mangiagalli e Regina Elena, Milano, Italy, ⁴Ospedale di Circolo e Fondazione Macchi, Varese, Italy, ⁵Casa di Cura S. Pio X, Milano, Italy, ⁶Ospedale Policlinico Santa Chiara, Pisa, Italy, ⁷Azienda Ospedaliera Careggi, Firenze, Italy

POSTER PRESENTATIONS SESSION II
SET-UP:	Monday, 26 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Monday, 26 October, 8:00 – 19:00
POSTER AUTHOR DISCUSSION HOUR:	Monday, 26 October, 17:30 – 18:30
DISMANTLE:	Monday, 26 October, 19:00 – 19:30

MENTAL HEALTH Clinical Outcomes Studies
PMH1	COMPLIANCE WITH ANTIPSYCHOTIC DRUGS AND HOSPITALIZATION: A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF PEOPLE WITH SCHIZOPHRENIA
	Moisan J, Grégoire JP Université Laval, Québec, QC, Canada

PMH2	EVIDENCE FOR SSRI IN THE TREATMENT OF DEPRESSION: EARLY KNOWLEDGE GAIN – LATE CONSEQUENCES IN ROUTINE CARE?
	Gothe H, Klein S, Storz P, Haeussler B IGES Institut GmbH, Berlin, Germany

PMH3	OVERCOMING THE CHALLENGES OF MODELLING SCHIZOPHRENIA: A UK CASE STUDY OF THE COST-EFFECTIVENESS OF OLANZAPINE LONG-ACTING INJECTION VS. RISPERIDONE LONG-ACTING INJECTION
	Carroll SM¹, Jemiai N², Moller J¹, Novick D³ ¹United BioSource Corporation (UBC), London, UK, ²Eli Lilly and Company, Erl Wood ELCL, UK, ³Eli Lilly and Company, Windlesham, Surrey, UK

PMH4	A SYSTEMATIC REVIEW OF THE REAL-WORLD STUDY EVIDENCE COMPARING THE SAFETY AND TOLERABILITY OF DONEPEZIL, RIVASTIGMINE AND GALANTAMINE FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE
	Lockhart I¹, Mitchell S², Kelly S³ ¹Pfizer Limited, Tadworth, UK, ²Abacus International, Bicester, UK, ³Pfizer, Tadworth, Surrey, UK

PMH5	USING TREEMAPS TO ASSESS PHYSICAL COMORBIDITY RISK IN PATIENTS WITH BIPOLAR DISORDER
	Marder WD¹, Stranges E², Houchens B³, Coffey R⁴, Wang SS¹, Schabert L³, Kassed C⁴, Mark TL⁵ ¹Thomson Reuters, Cambridge, MA, USA, ²Thomson Reuters, Evanston, IL, USA, ³Thomson Reuters, Santa Barbara, CA, USA, ⁴Thomson Reuters, Washington, DC, USA, ⁵Thomson Healthcare, Inc, Washington, DC, USA

PMH6	IMPACT OF COMORBIDITIES ON ANTIDEPRESSANT INITIATION: DULOXETINE, VENLAFAXINE, AND ESCITALOPRAM VERSUS OTHER SSRIS
	Liu X¹, Chen Y², Faries D², Miner C², Swindle R¹ ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Lilly USA, LLC, Indianapolis, IN, USA

PMH7	EFFICACY OF ANTIPSYCHOTICS IN THE PREVENTION OF SCHIZOPHRENIA RELAPSE: A SYSTEMATIC REVIEW OF DOUBLE BLIND RANDOMISED CONTROLLED TRIALS
	Meier G, Edwards SJ, von Maltzahn R AstraZeneca UK Ltd, Luton, UK

PMH8	CLINICAL EFFICACY AND SAFETY OF DULOXETINE IN COMPARISON WITH PLACEBO IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN POLAND
	Pankiewicz O¹, Jagodzinska K¹, Rys P¹, Lach K¹, Jarczewska D¹, Cel M², Mierzejewski P², Bartminski W³, Plisko R¹, Wladysiuk M¹ ¹HTA Consulting, Krakow, Poland, ²Eli Lilly, Warsaw, Poland, ³Eli Lilly, Windlesham, Surrey, UK

PMH9	A SYSTEMATIC REVIEW OF PHARMACOLOGICAL TREATMENTS FOR BIPOLAR I MANIA
	Parkinson BT¹, von Maltzahn R² ¹AstraZeneca UK Ltd, Luton, Bedfordshire, UK, ²AstraZeneca UK Ltd, Luton, UK

PMH10	EFFECTIVENESS AND COST-EFFECTIVENESS OF LIFESTYLE INTERVENTIONS IN PERSONS WITH SEVERE MENTAL DISORDERS. A SYSTEMATIC REVIEW
	Verhaeghe N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L Ghent University, Ghent, Belgium

PMH11	DIFFERENCES BETWEEN CHILDREN AND ADOLESCENTS IN TREATMENT RESPONSE TO ATOMOXETINE AND THE CORRELATION BETWEEN QOL AND ADHD CORE SYMPTOMS
	Schacht A¹, Escobar R², Savill NC³, Wagner T¹, Wehmeier PM¹ ¹Lilly Deutschland GmbH, Bad Homburg, Germany, ²Lilly Spain, Madrid, Spain, ³Lilly UK, Basingstoke, UK

PMH12	COMPARISON OF POLYPHARMACY VS MONOTHERAPY ON OCCURRENCE OF RELAPSE IN SCHIZOPHRENIC PATIENTS - ADVANTAGE OF PROPENSITY SCORING ADJUSTMENT
	Sarlon E¹, Millier A², Cristeau O², Toumi M³ ¹CREATIV-CEUTICAL, Paris, France, ²CREATIV-CEUTICAL, PARIS, France, ³University Claude Bernard Lyon I, Villeurbanne Cedex, France

PMH13	TIME TO OPTIMIZATION OF DOSE IN PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): DATA FROM THE NETHERLANDS
	Sasane R, Hodgkins P Shire Pharmaceuticals, Wayne, PA, USA

PMH14	ALZHEIMER'S DISEASE: A PHARMACOEPIDEMIOLOGICAL STUDY
	Truter I Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa

PMH15	INITIAL HIGH-DOSE PRESCRIPTION OF DULOXETINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: DEMOGRAPHIC AND CLINICAL PREDICTORS
	Liu X¹, Gelwicks SC², Able S¹, Faries D², Watson PR¹, Robinson M², Johnstone BM¹ ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Lilly USA, LLC, Indianapolis, IN, USA

PMH16	PREDICTIVE FACTORS FOR HOSPITALIZATION IN FRENCH SCHIZOPHRENIC PATIENTS
	Sarlon E¹, Dorey J¹, Millier A¹, Toumi M² ¹CREATIV-CEUTICAL, PARIS, France, ²University Claude Bernard Lyon I, Villeurbanne Cedex, France

PMH17	PREVALENCE, INCIDENCE AND PERSISTENCE OF ANTIDEPRESSANT DRUG PRESCRIBING IN THE ITALIAN GENERAL POPULATION: RETROSPECTIVE DATABASE ANALYSIS
	Menditto E, De Portu S, Citarella A, Cammarota S, Riegler S, Mantovani LG University of Naples, Naples, Italy

PMH18	SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE
	Dragomir A¹, Angers JF¹, Tarride JE², Rouleau G¹, Drapeau P¹, Perreault S¹ ¹University of Montreal, Montréal, QC, Canada, ²McMaster University, Hamilton, ON, Canada

PMH19	MEASUREMENT OF CHRONIC STRESS BETWEEN PEOPLE WORKING IN PROFIT-ORIENTED ENVIRONMENT
	Dér A¹, Pakai A¹, Németh K¹, Kriszbacher I¹, Zsigmond E¹, Boncz I¹, Vattay P² ¹University of Pécs, Pécs, Hungary, ²University of Pécs, Zalaegerszeg, Hungary

PMH20	IMPACT OF DISEASE SEVERITY ON DURATION OF HOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH OLANZAPINE OR HALOPERIDOL IN GERMANY: POST-HOC ANALYSIS OF DATA COLLECTED IN THE GEO STUDY
	Clouth J¹, Schmidt P², Möser G³, Eichmann F⁴, Breitscheidel L⁴ ¹Lilly Deutschland GmbH, Bad Homburg, Germany, ²University of Giessen, Giessen, Germany, ³Masem Research Institute, Giessen, Germany, ⁴Kendle GmbH, Munich, Germany

MENTAL HEALTHCost Studies
PMH21	BUDGET IMPACT ANALYSIS OF DULOXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER
	Gwiosda B¹, Rutkowski J¹, Rys P¹, Plisko R¹, Wladysiuk M¹, Cel M², Mierzejewski P², Bartminski W³ ¹HTA Consulting, Krakow, Poland, ²Eli Lilly, Warsaw, Poland, ³Eli Lilly, Windlesham, Surrey, UK

PMH22	BUDGET IMPACT OF THE USE OF RISPERIDONE LONG ACTING INJECTABLE IN THE GERMAN HEALTH CARE SYSTEM
	Gaudig M, Fleischmann J, Püschner F Janssen-Cilag GmbH, Neuss, Germany

PMH23	LABELLED DRUG-RELATED HEALTH PUBLIC EXPENDITURE IN RELATION TO GROSS DOMESTIC PRODUCT IN EUROPE
	Prieto L European Monitoring Centre for Drugs and Drug Addiction, Lisboa, Lisboa, Portugal

PMH24	ECONOMIC BENEFITS OF ESCITALOPRAM VERSUS DULOXETINE IN SPAIN
	Danchenko N¹, Despiégel N¹, Marteau F¹, Herranz del Rey S² ¹Lundbeck SAS, Paris, France, ²Lundbeck Spain, Barcelona, Spain

PMH25	CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NON-ADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/MIXED EPISODE OF BIPOLAR DISORDER: RESULTS FROM THE EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF MEDICATION (EMBLEM) STUDY
	Hong J¹, Reed C², Novick D², Haro JM³, Aguado J³ ¹London School of Economics, London, UK, ²Eli Lilly and Company, Windlesham, Surrey, UK, ³Sant Joan de Deu-SSM, Barcelona, Spain

PMH26	A COMPARISON OF TREATMENT PATTERNS AND COSTS FOR SUBJECTS NEWLY TREATED WITH DONEPEZIL VERSUS THOSE NEWLY TREATED WITH GALANTAMINE OR RIVASTIGMINE
	Ye X(¹, Roberts CS², Hoffman DL³, Liu F¹, Iorga SR⁴ ¹i3 Innovus, An Ingenix Company, Eden Prairie, MN, USA, ²Pfizer Inc, New York, NY, USA, ³Pfizer, Inc, New London, CT, USA, ⁴i3 Innovus, an Ingenix Company, Eden Prairie, MN, USA

PMH27	COMPARISON OF COST FOR DIFFERENT TESTS OF DEMENTIA SCREENING
	Navarro Espigares JL¹, Carnero Pardo C¹, Hernández Torres E¹, Espejo Martinez B¹, Espinosa Garcia M², Saez Zea CR¹, Lopez Alcalde S³, Vilchez Carrillo RM¹ ¹University Hospital Virgen de las Nieves, Granada, Spain, ²FIDYAN Neurocenter, Granada, Spain, ³University Hospital Virgen de las Nieves, Granada, SC, Spain

PMH28	INITIAL PRESCRIPTION DOSE OF DULOXETINE AND HOSPITALIZATION AND HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER
	Liu X¹, Gelwicks SC², Faries D², Watson PR¹, Johnstone BM¹ ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Lilly USA, LLC, Indianapolis, IN, USA

PMH29	DIFFERENCES IN HEALTH CARE USES AFTER TREATMENT OF DULOXETINE VERSUS OTHER ANTIDEPRESSANTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN VETERANS AFFAIRS HEALTH CARE NETWORK
	Shi L¹, Liu J¹, Zhao Y² ¹Tulane University, New Orleans, LA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PMH30	A DYNAMIC MARKOV APPROACH ASSESSING THE BURDEN OF ILLNESS OF GENERALIZED ANXIETY (GAD) DISORDER IN CANADA
	Bereza BG¹, Machado M¹, Papadimitropoulos M², Sproule B³, Ravindran AV³, Einarson TR¹ ¹University of Toronto, Toronto, ON, Canada, ²Eli Lilly & Company, Toronto, ON, Canada, ³Centre for Addiction and Mental Health and University of Toronto, Toronto, ON, Canada

PMH31	MEASURING THE ECONOMIC BURDEN OF DEPRESSION USING PATIENT RECORDS
	Jacobs P¹, Ohinmaa A², Escober-Doran C¹, Patterson S³, Slomp M³ ¹Institute of Health Economics, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Alberta Health Services, Edmonton, AB, Canada

PMH32	COST OF SCHIZOPHRENIA IN FRANCE
	Heider D¹, Angermeyer MC², Millier A³, Konig HH⁴, Azorin JM⁵, Toumi M⁶ ¹Universität Leipzig, Leipzig, Germany, ²University of Leipzig, Leipzig, Saxony, Germany, ³CREATIV-CEUTICAL, Paris, France, ⁴University of Leipzig, Leipzig, Germany, ⁵SHU de Psychiatrie d'Adultes, MARSEILLES, France, ⁶University Claude Bernard Lyon I, Villeurbanne Cedex, France

PMH33	BURDEN OF BIPOLAR DISORDER: WHAT ARE WE REALLY MEASURING?
	Gil E¹, Medina E¹, Cordero L², Valero G¹, Rovirosa A¹ ¹AstraZeneca Farmacéutica Spain S.A., Madrid, Spain, ²AstraZeneca Farmacéutica Spain S.A, Madrid, Spain

PMH34	COSTS OF SCHIZOPHRENIA WITHIN A LARGE GERMAN STATUTORY HEALTH INSURANCE FUND
	Zeidler J¹, Mittendorf T², Greiner W³ ¹Leibniz University of Hannover, Hannover, Germany, ²Herescon gmbh, Hannover, Germany, ³University of Bielefeld, Bielefeld, Germany

PMH35	BURDEN OF ILLNESS AND COMORBIDITIES IN ADULT PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
	Montejano LB¹, Sasane R², Hodgkins P², Huse D³ ¹Thomson Reuters, Washington, DC, USA, ²Shire Pharmaceuticals, Wayne, PA, USA, ³Thomson Reuters, Cambridge, MA, USA

PMH36	MENTAL HEALTH COSTS INCURRED BY PATIENTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER WHO DO NOT RESPOND TO SUCCESSIVE LINES OF TREATMENT
	Svedsater H¹, Harrow B², Wu N², Ozer-Stillman I², Locklear JC³ ¹AstraZeneca Pharmaceuticals, Sodertalje, Sweden, ²Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ³AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PMH37	COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN DULOXETINE-REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER: AN ECONOMIC EVALUATION UNDER MEDICAL USUAL PRACTICE IN MENTAL HEALTH CENTERS
	Carrasco JL¹, Olivares JM², Alvarez E³, de Salas M⁴, Rejas J⁵ ¹Hospital Clínico San Carlos, Madrid, Spain, ²Hospital Meixoeiro - Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain, ³Santa Creu i Sant Pau Hospital, Barcelona, Spain, ⁴Pfizer Spain, Alcobendas (Madrid), Spain, ⁵Pfizer Spain, Madrid, Spain

PMH38	COST-EFFECTIVENESS OF PREGABALIN VERSUS ISRS/ISRN IN BENZODIAZEPINE-REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER: AN ECONOMIC EVALUATION UNDER MEDICAL USUAL PRACTICE IN MENTAL HEALTH CENTERS
	Olivares JM¹, Alvarez E², Carrasco JL³, Barrueta A⁴, López-Gómez V⁵, Rejas J⁵ ¹Hospital Meixoeiro - Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain, ²Santa Creu i Sant Pau Hospital, Barcelona, Spain, ³Hospital Clínico San Carlos, Madrid, Spain, ⁴Pfizer Spain, Alcobendas (Madrid), Spain, ⁵Pfizer Spain, Madrid, Spain

PMH39	COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER: A NESTED-CASE-CONTROL ECONOMIC EVALUATION UNDER USUAL MEDICAL PRACTICE IN MENTAL HEALTH CENTERS.
	Alvarez E¹, Carrasco JL², Olivares JM³, Ferro MB⁴, Pérez M⁴, Rejas J⁵ ¹Santa Creu i Sant Pau Hospital, Barcelona, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Meixoeiro - Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain, ⁴Pfizer Spain, Alcobendas (Madrid), Spain, ⁵Pfizer Spain, Madrid, Spain

PMH40	COST-EFFECTIVENESS ANALYSIS OF THE INCREDIBLE YEARS PARENT PROGRAM AS A PREVENTIVE INTERVENTION
	Posthumus J¹, Mangen MJ¹, Raaijmakers M¹, De Wit GA², van Engeland H¹, Matthys W¹ ¹University Medical Center Utrecht, Utrecht, The The Netherlands, ²National Institute for Public Health and the Environment, Bilthoven, The The Netherlands

PMH41	COST-EFFECTIVENESS ANALYSIS OF ANTI-PSYCHOTICS BY ROUTE IN SCHIZOPHRENIA
	Kim BRM, Yang BM, Lee TJ Seoul National University, Seoul, South Korea

PMH42	COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY
	Carroll SM¹, Jemiai N², Suter B³, O'Donohoe P⁴, Skjoldborg U⁵, Moller J¹, Kleivenes OK³, Novick D⁶ ¹United BioSource Corporation (UBC), London, UK, ²Eli Lilly and Company, Erl Wood ELCL, UK, ³Eli Lilly Norge A.S, Oslo, Norway, ⁴United BioSource Corporation (UBC), London , UK, ⁵Eli Lilly, DK - 2800 Lyngby, Denmark, ⁶Eli Lilly and Company, Windlesham, Surrey, UK

PMH43	THE COST-EFFECTIVENESS OF QUETIAPINE XR IN THE PREVENTION OF RELAPSE AND HOSPITALIZATION IN SCHIZOPHRENIA
	Karamustafalioglu O¹, Ozdemir O², Kalo Z³ ¹Sisli Etfal Hospital, Istanbul, Turkey, ²Yorum Consultancy Ltd, Istanbul, Turkey, ³Eotvos Lorand University, Budapest, Hungary

PMH44	COST AND EFFECTIVENESS OF FLUPENTIXOL COMPARED TO OTHER FIRST AND SECOND GENERATION ANTIPSYCHOTIC AGENTS FOR THE TREATMENT OF SCHIZOPHRENIA IN ROUTINE CARE
	Stargardt T¹, Gericke CA², Juckel G³ ¹Helmholtz Zentrum Muenchen, Neuherberg, Germany, ²The University of Adelaide, Adelaide, South Australia, Australia, ³Ruhr University School of Medicine, Bochum, Germany

PMH45	COST-UTILITY OF AGOMELATINE, VENLAFAXINE AND PLACEBO IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN FINLAND – ECONOMIC MODELLING STUDY USING REPRESENTATIVE POPULATION DATA
	Soini EJ, Hallinen TA ESiOR Oy, Kuopio, Finland

PMH46	ESTIMATING THE COSTS OF PSYCHIATRIC HOSPITAL SERVICES IN NIGERIA; A CASE STUDY OF FEDERAL NEUROPSYCHIATRIC HOSPITAL ENUGU, SOUTH EAST NIGERIA
	Ezenduka CC University of Nigeria, Enugu Campus, Enugu, Nigeria

PMH47	ASSOCIATION BETWEEN ANTIPSYCHOTIC TREATMENT AND CLINICAL AND ECONOMIC OUTCOMES IN SCHIZOPHRENIA AND BIPOLAR DISORDER
	Sanders KN¹, Mychaskiw MA¹, Alvir J¹, Montejano LB², Lenhart G³, O'Gorman C¹ ¹Pfizer, New York, NY, USA, ²Thomson Medstat, Washington, DC, USA, ³Thomson Reuters, Cambridge, MA, USA

PMH48	COST-EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE VERSUS PAROXETINE AND LITHIUM IN ACUTE BIPOLAR DEPRESSION
	Meier G, von Maltzahn R, Parkinson BT AstraZeneca UK Ltd, Luton, UK

PMH49	COST-EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE VERSUS OTHER ATYPICAL ANTIPSYCHOTICS IN ACUTE BIPOLAR DEPRESSION
	Meier G, Edwards SJ, von Maltzahn R AstraZeneca UK Ltd, Luton, UK

PMH50	CLINICAL VALIDITY OF REMISSION IN PATIENTS WITH MAJOR DEPRESSION IN POPULATION DATABASES
	Sicras-Mainar A¹, Blanca-Tamayo M¹, Navarro-Artieda R², Gutiérrez-Nicuesa L³, Salvatella-Pasant J⁴ ¹Badalona Serveis Assistencials SA, Barcelona, Spain, ²Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, ³Lundbeck España SA, Barcelona, Spain, Spain, ⁴Lundbeck España SA, Barcelona, Spain

PMH51	TRENDS IN RATES OF PEDIATRIC BIPOLAR DISORDER-RELATED HOSPITALIZATIONS AND RELATED RESOURCE USE IN THE UNITED STATES
	Jackel J¹, Davis KL², Candrilli SD² ¹RTI Health Solutions, Waltham, MA, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA

PMH52	PATIENT-REPORTED OUTCOMES IN A VULNERABLE POPULATION: A PILOT STUDY CONDUCTED WITH A NOVEL PATIENT COMMUNITY
	Cascade EF¹, Stephenson H² ¹iGuard.org, Falls Church, VA, USA, ²iGuard, Inc, Princeton, NJ, USA

PMH53	PATTERNS OF HEALTH CARE RESOURCE UTILIZATION IN JAPANESE PSYCHIATRIC OUTPATIENTS: RESULTS FROM THE ONE-DAY SURVEY CONDUCTED BY THE JAPANESE ASSOCIATION OF NEURO-PSYCHIATRIC CLINICS
	Inagaki A¹, Tomita N¹, Nishimura Y², Hatou K², Hirakawa H³ ¹Keio University Graduate School of Health Management, Fujisawa, Kanagawa, Japan, ²Japanese Association of Mental Health Services, Shibuya-ku, Tokyo, Japan, ³Japanese Association of Neuro-Psychiatric Clinics, Shibuya-ku, Tokyo, Japan

PMH54	COMPLEX ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: PATIENT CHARACTERISTICS, HEALTH CARE UTILIZATION AND COSTS IN A RETROSPECTIVE OBSERVATIONAL CLAIMS STUDY
	Hess G¹, Sasane R², Hill J¹, Hodgkins P², Shah MR¹ ¹SDI Health, Plymouth Meeting, PA, USA, ²Shire Pharmaceuticals, Wayne, PA, USA

MENTAL HEALTH Patient-Reported Outcomes Studies
PMH55	WITHDRAWN


PMH56	A PATIENT PERSPECTIVE ON SIDE EFFECTS OF ANTIPSYCHOTIC THERAPY: THE TOOL INSTRUMENT
	Lindström E¹, Jönsson L², Berntsson A³ ¹Malmö University Hospital, Malmö, Sweden, ²i3 Innovus, Stockholm, Sweden, ³Danderyds hospital, STOCKHOLM, Sweden

PMH57	NON-ADHERENCE TO ORAL ANTIPSYCHOTICS IN SCHIZOPHRENIA: RELAPSE AND UTILIZATION OF HEALTH CARE RESOURCES IN A 6-MONTH FOLLOW-UP PERIOD
	San L¹, Valladares A², Bernardo M³, Olivares JM⁴, Ciudad A², García-Polavieja P², Yruretagoyena B², Dilla T², Gilaberte I² ¹Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain, ²Lilly, S.A., Alcobendas, Madrid, Spain, ³Hospital Clinic, Barcelona, Barcelona, Spain, ⁴Hospital Meixoeiro - Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain

PMH58	TOOL: MULTI-ATTRIBUTE UTILITY FUNCTION REFLECTING PATIENT EXPERIENCE OF SIDE EFFECTS TO ANTIPSYCHOTIC THERAPY
	Jönsson L¹, Lang A², Lindström E³ ¹i3 Innovus, Stockholm, Sweden, ²i3 Innovus, 11164, Sweden, ³Malmö University Hospital, Malmö, Sweden

PMH59	FURTHER VALIDITY EVIDENCES OF THE GENERALIZED ANXIETY DISORDER – 7 SCALE (GAD-7)
	Ruiz MA¹, Zamorano E², García-Campayo J³, Pardo A¹, Freire O⁴, Rejas J⁴ ¹Universidad Autónoma de Madrid, Madrid, Spain, ²Sant Antoni de Vilamajor Primary Care Center, ABS Alt Mogent, Barcelona, Spain, ³Hospital Miguel Servet, Zaragoza, Spain, ⁴Pfizer Spain, Madrid, Spain

PMH60	A CONCEPTUAL MODEL OF ‘CLEAR THINKING' RELEVANT TO PATIENTS DIAGNOSED WITH SCHIZOPHRENIA
	Bridges JF¹, dosReis SC², Margolis RL², Everett AS³ ¹Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, ²Johns Hopkins University, School of Medicine, Baltimore, MD, USA, ³Johns Hopkins Bayview Medical Center, Baltimore, MD, USA

PMH61	PATIENTS PREFERENCES IN ADULTS WITH ADHD – A DISCRETE CHOICE EXPERIMENT
	Mühlbacher AC¹, Slawik L², Kasper J³, Nübling M⁴ ¹Hochschule Neubrandenburg, Neubrandenburg, Germany, ²Janssen Cilag GmbH, Neuss, Germany, ³GEB: Gesellschaft für Empirische Beratung mbH – Empirical Consulting -, Freiburg, Germany, ⁴Gesellschaft für empirische Beratung mbH, D- 79211 Denzlingen, Germany

PMH62	THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: VALIDATION OF A SPECIFIC MEASURE TO EVALUATE HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER
	Maurino J¹, Cordero L², Montejo AL³, Correas Lauffer J⁴, Cuervo J⁵, Rebollo P⁵, Diez T², Hernandez R² ¹AstraZeneca, Madrid, Spain, ²AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, ³Hospital Universitario de Salamanca, Salamanca, Spain, ⁴Hospital del Henares, Coslada, Spain, ⁵BAP Health Outcomes Research, Oviedo, Spain

PMH63	ESTIMATION OF A MULTI-ATTRIBUTE UTILITY FUNCTION FOR THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE
	Cordero L¹, Montejo AL², Correas Lauffer J³, Villa G⁴, Rebollo P⁵, Maurino J¹, Diez T¹, Hernandez R¹ ¹AstraZeneca Farmacéutica Spain S.A, Madrid, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital del Henares, Coslada, Spain, ⁴BAP Health Outcomes, Oviedo, Asturias, Spain, ⁵BAP Health Outcomes Research, Oviedo, Spain

PMH64	THE POSTTRAUMATIC STRESS AMONG AMBULANCE PERSONNEL IN HUNGARY
	Betlehem J¹, Nagy É¹, Oláh A¹, Boncz I¹, Sebestyén A², Marton-Simora J¹, Nagy G¹, Deutsch K¹, Kriszbacher I¹, Göndöcs Z³ ¹University of Pécs, Pécs, Hungary, ²National Health Insurance Fund Administration, Pécs, Hungary, ³National Ambulance Service, Budapest, Hungary

PMH65	ASSOCIATION BETWEEN EARLY ANTIDEPRESSANT RESPONSE AND QUALITY OF LIFE AMONG PATIENT WITH DEPRESSION: RESULTS FROM A 1-YEAR FOLLOW-UP LARGE EPIDEMIOLOGICAL STUDY
	Roca M¹, Valladares A², Alvarez E³, Baca E⁴, Caballero L⁴, Ciudad A², García-Polavieja P², Casillas M², Yruretagoyena B², Dilla T², Gilaberte I² ¹Joan March Hospital, Palma de Mallorca, Illes Balears, Spain, ²Lilly, S.A., Alcobendas, Madrid, Spain, ³Santa Creu i Sant Pau Hospital, Barcelona, Barcelona, Spain, ⁴Hospital Puerta de Hierro, Madrid, Madrid, Spain

PMH66	QUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES: COMPARISONS OF INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ORAL AND LONG-ACTING INJECTABLE FORMULATIONS OF OLANZAPINE
	Godfrey JL¹, Detke HC¹, Montgomery WS², Zhao F¹, McDonnell D¹ ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Eli Lilly Australia, West Ryde, NSW, Australia

PMH67	QUALITY OF LIFE OF OUTPATIENT DEMENTED PATIENTS IN HUNGARY
	Érsek K¹, Karpati K¹, Brodszky V¹, Péntek M², Boncz I³, Kovács T⁴, Gulácsi L¹ ¹Corvinus University of Budapest, Budapest, Hungary, ²Flor Ferenc County Hospital, Kistarcsa, Hungary, ³University of Pécs, Pécs, Hungary, ⁴Semmelweis University, Budapest, Hungary

PMH68	IMPACT OF DEMENTIA UPON CAREGIVER EMPLOYMENT & QUALITY OF LIFE
	Piercy J, Jackson J, Jones E, Anderson P Adelphi Real World, Bollington, Cheshire, UK

MENTAL HEALTH Health Care Use & Policy Studies
PMH69	WITHDRAWN

PMH70	DAILY AVERAGE CONSUMPTION AND AVERAGE DAILY COSTS OF DULOXETINE, VENLAFAXINE-XR, AND PREGABALIN AMONG US COMMERCIALLY INSURED PATIENTS
	Able S, Watson PR, Zhao Y Eli Lilly and Company, Indianapolis, IN, USA

PMH71	SOCIODEMOGRAPHIC FACTORS AND TOXIC HABITS RELATED TO STUDENT DRUG USE: THE CASE OF THE TECHNOLOGICAL EDUCATIONAL INSTITUTE OF ATHENS
	Carayanni V, Papageorgiou E, Demsia S, Roussou K, Zafiri M TECHNOLOGICAL EDUCATIONAL INSTITUTE OF ATHENS, EGALEO, ATTIKI, Greece

PMH72	BENZODIAZEPINE USE AMONG FREQUENT ATTENDERS TO EMERGENCY DEPARTMENTS: A NATIONWIDE STUDY IN TAIWAN
	Chou LF¹, Chen TJ² ¹National Chengchi University, Taipei, Taiwan, ²Taipei Veterans General Hospital, Taipei, Taiwan

PMH73	POTENTIAL ABUSE OF COMBINATION ANALGESICS: A DATABASE ANALYSIS
	Truter I, Knoesen BC Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa

PMH74	REIMBURSEMENT OF INNOVATIVE DRUGS IN SLOVAKIA - PHARMACOECONOMICS OF AGOMELATIN IN DEPRESSION
	Tomek D¹, Psenkova M², Hanzelova M³ ¹Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, ²Pharm-In, Bratislava, Slovak Republic, ³Servier Slovakia, Bratislava, Slovak Republic

PMH75	PREDICTORS AND COSTS OF MDD TREATMENT WITH DULOXETINE COMPARED WITH VENLAFAXINE EXTENDED RELEASE
	Swindle R¹, Ye W², Robinson RL¹, Zhao Y¹ ¹Eli Lilly and Company, Indianapolis, IN, USA, ²Lilly USA, LLC, Indianapolis, IN, USA

PMH76	PREDICTORS FOR DULOXETINE TREATMENT FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN VETERANS AFFAIRS HEALTH CARE NETWORK
	Shi L¹, Liu J¹, Zhao Y² ¹Tulane University, New Orleans, LA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

POSTER PRESENTATIONS SESSION II
SET-UP:	Monday, 26 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Monday, 26 October, 8:00 – 19:00
POSTER AUTHOR DISCUSSION HOUR:	Monday, 26 October, 17:30 – 18:30
DISMANTLE:	Monday, 26 October, 19:00 – 19:30

NEUROLOGICAL DISORDERS Clinical Outcomes Studies


PND1	RELATIONSHIP BETWEEN ADHERENCE TO INTERFERONS TO TREAT MULTIPLE SCLEROSIS AND THE NUMBER AND SEVERITY OF RELAPSES
	Faris R¹, Steinberg S¹, Chang CF², Tang J¹, Tankersley MA¹ ¹Accredo Health Group, Memphis, TN, USA, ²University of Memphis, Memphis, TN, USA

PND2	A BAYESIAN META-ANALYSIS COMPARING TREATMENTS FOR ALZHEIMER'S DISEASE
	Gilligan A¹, Malone DC² ¹University of Arizona, Tucson, AZ, USA, ²University of Arizona, College of Pharmacy, Tucson, AZ, USA

PND3	EFFICACY AND TOLERABILITY OF NATALIZUMAB IN RELAPSING MULTIPLE SCLEROSIS; A META-ANALYSIS
	Nikfar S¹, Rahimi R², Rezaie A³, Abdollahi M² ¹Iranian Ministry of Health and Medical Education, Tehran, Iran, ²Tehran University of Medical Sciences, Tehran, Iran, ³University of Alberta, Edmonton, Alberta, Canada

PND4	THE FEATURES OF MULTIPLE SCLEROSIS IN IRAN
	Khanizadeh H¹, Izham M², Shafie AA², Nikkhah K³ ¹University Sains Malaysia(USM), Penang, Malaysia, ²University Sains Malaysia, Penang, Malaysia, ³Mashhad University of Medical Sciences, Mashhad, Iran

NEUROLOGICAL DISORDERS Cost Studies
PND5	BUDGET IMPACT ANALYSIS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN VARIOUS ITALIAN REGIONS: THE ROLE OF VENLAFAXINE
	Di Matteo S¹, Colombo GL² ¹S.A.V.E. Studi Analisi Valutazioni Economiche, Milan, Italy, ²S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Milano, Italy

PND6	ESTIMATION OF PER-MEMBER-PER-YEAR COSTS FOR MANAGING FALLS OR FRACTURES AMONG HYPNOTIC USERS IN A MANAGED CARE PLAN

	Koerber C¹, Joish VN², Camacho F³, Balkrishnan R⁴, Zammit G⁵ ¹VIE, Marseille, Paca, France, ²Sanofi-aventis, Bridgewater, NJ, USA, ³Penn State College of Medicine, Hershey, PA, USA, ⁴Ohio State University College of Pharmacy, Columbus, OH, USA, ⁵Columbia University College of Physicians & Surgeons, New York, NY, USA

PND7	BUDGET IMPACT AND COST – EFFECTIVENESS OF SUGAMMADEX IN THE REVERSAL OF PATIENTS WITH NEUROMUSCULAR BLOCK
	Sabater FJ¹, Aguilera L², Canet J³, Echevarria M⁴, Lora-Tamayo JI⁵, Poveda JL⁶, Sabaté A⁷, López-Belmonte JL⁸ ¹Schering-Plough S.A, Alcobendas, Spain, ²Hospital de Basurto, Bilbao, País Vasc, Spain, ³Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, ⁴Hospital Nuestra Señora de Valme, Sevilla, Andalucia, Spain, ⁵Hospital Infanta Sofía, San Sebastian de los Reyes, Madrid, Spain, ⁶Hospital Universitario La Fe, Valencia, Spain, ⁷Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain, ⁸Schering Plough S.A, Alcobendas, Madrid, Spain

PND8	COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
	Espallardo O¹, Crespo C², Polanco C¹, Nieves D² ¹Merck Serono, Madrid, Spain, ²Oblikue Consulting, Barcelona, Spain

PND9	COST-EFFECTIVENESS AND BUDGET IMPACT MODELLING OF LACOSAMIDE IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN FINLAND
	Soini EJ¹, Martikainen JA², Vanoli A³ ¹ESiOR Oy, Kuopio, Finland, ²ESiOR Oy and Department of Social Pharmacy, University of Kuopio, Kuopio, Finland, ³HERON Health, Luton, UK

PND10	COST ANALYSIS OF ACTIVA RC®: RECHARGABLE NEUROESTIMULATOR FOR DEEP BRAIN ESTIMULATION THERAPY (DBS)
	Valldeoriola F¹, González P², Annoni E³ ¹Clinic Hospital, Barcelona, Spain, ²Medtronic Iberia, Madrid, Spain, ³Medtronic International Trading Sàrl, Tolochenaz, Switzerland

PND11	NEW ACTIVA PC® FAMILY: COST ANALYSIS OF THE NEW FEATURES FOR DEEP BRAIN STIMULATION THERAPY (DBS)
	Valldeoriola F¹, González P², Rodriguez JM² ¹Clinic Hospital, Barcelona, Spain, ²Medtronic Iberia, Madrid, Spain

PND12	COST AND RESOURCE USE RELATED TO NEWLY DIAGNOSED MULTIPLE SCLEROSIS: REAL-WORLD DATA FROM A LARGE US CLAIMS DATABASE
	Singer ME¹, Asche CV², Chung H³, Jhaveri M⁴, Miller A⁵ ¹Case Western Reserve University School of Medicine, Cleveland, OH, USA, ²University of Utah College of Pharmacy, Salt Lake City, UT, USA, ³Rutgers University, Piscataway, NJ, USA, ⁴sanofi-aventis USA, Bridgewater, NJ, USA, ⁵Mount Sanai School of Medicine, New York, NY, USA

PND13	IMPACT OF CHRONIC (CM) AND EPISODIC MIGRAINE (EM) ON WORK PRESENTEEISM IN 9 COUNTRIES
	Varon SF¹, Burk CT², Buse DC³, Kawata AK⁴, Payne KA⁵, Blumenfeld A⁶, Lipton RB⁷ ¹Allergan Inc., Irvine, CA, USA, ²Caroline Burk Inc., Laguna Beach, CA, USA, ³Montefiore Headache Center, Bronx, NY, USA, ⁴United BioSource Corporation, Bethesda, MD, USA, ⁵United BioSource Corporation, Montreal, QC, Canada, ⁶The Headache Center of Southern California, Del Mar, CA, USA, ⁷Albert Einstein College of Medicine, Bronx, NY, USA

PND14	COSTS OF ILLNESS IN PARKINSON'S DISEASE IN SIX EUROPEAN COUNTRIES
	von Campenhausen S, Winter Y, Reese JP, Dodel R Philipps-University, Marburg, Germany

PND15	THE POTENTIAL ECONOMIC IMPACT OF GENERIC SUBSTITUTION OF TOPIRAMATE ON HEALTH CARE COSTS IN THE G4 EUROPEAN COUNTRIES
	Paradis PE¹, Latremouille-Viau D¹, Moore Y¹, Mishagina N¹, Lafeuille MH¹, Lefebvre P¹, Gaudig M², Duh MS³ ¹Groupe d'analyse, Ltee, Montreal, QC, Canada, ²Janssen-Cilag, Neuss, Germany, ³Analysis Group, Inc., Boston, MA, USA

PND16	ECONOMIC IMPACT OF GENERIC ENTRY OF TOPIRAMATE IN GERMANY: CONVERSION OF THE CANADIAN EXPERIENCE INTO THE SETTINGS OF GERMANY
	Paradis PE¹, Latremouille-Viau D¹, Moore Y¹, Mishagina N¹, Lafeuille MH¹, Lefebvre P¹, Gaudig M², Duh MS³ ¹Groupe d'analyse, Ltee, Montreal, QC, Canada, ²Janssen-Cilag, Neuss, Germany, ³Analysis Group, Inc., Boston, MA, USA

PND17	THE COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PARKINSON'S DISEASE PATIENTS
	Dams J¹, Siebert U², Bornschein B², Volkmann J³, Deuschl G³, Oertel WH¹, Reese JP¹, Dodel R¹ ¹Philipps-University, Marburg, Germany, ²UMIT University of Health Sciences, Medical Informatics, and Technology, Hall i. T, Austria, ³Christian-Albrechts-University, Kiel, Germany

PND18	COST-EFFECTIVENESS OF A NEW ABSORBABLE HYDROGEL FOR THE PREVENTION OF CSF LEAKS IN FRENCH HOSPITALS
	Castanier JC¹, Maunoury F², Hédoux S³, Auffrand M³ ¹Independent Consultant in Health Economics, Lyon, France, ²STATESIA, Le Mans, France, ³FRAVIMED, Lyon, France

PND19	COST – EFFECTIVENESS OF SUGAMMADEX IN THE MANAGEMENT OF PATIENTS WITH UNANTICIPATED DIFFICULT INTUBATION AND PATIENTS NEEDING RAPID SEQUENCE INTUBATION
	Sabater FJ¹, Aguilera L², Canet J³, Echevarria M⁴, Lora-Tamayo JI⁵, Poveda JL⁶, Sabaté A⁷, López-Belmonte JL¹ ¹Schering Plough S.A, Alcobendas, Spain, ²Hospital de Basurto, Bilbao, País Vasco, Spain, ³Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, ⁴Hospital Nuestra Señora de Valme, Sevilla, Andalucia, Spain, ⁵Hospital Infanta Sofía, San Sebastian de los Reyes, Madrid, Spain, ⁶Hospital Universitario La Fe, Valencia, Spain, ⁷Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain

PND20	REVERSAL OF NEUROMUSCULAR BLOCKADE WITH SUGAMMADEX – COST-EFFECTIVENESS ANALYSIS
	Calado F¹, Félix J², Rabiais S¹, Vilela H³ ¹Exigo Consultores, Alhos Vedros, Portugal, ²Exigo Consultores, Alhos Vedros, Lisbon, Portugal, ³Hospital Fernando Fonseca, Amadora, Portugal

PND21	COST-EFFECTIVENESS OF RASAGILINE COMPARED TO OTHER FIRST LINE TREATMENT OPTIONS OF EARLY PARKINSON'S DISEASE IN THE UNITED STATES
	Farkouh R¹, Wilson MR¹, Tarrants ML², Castelli-Haley J², Armand C³ ¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Teva Neuroscience, Kansas City, MO, USA, ³H. Lundbeck A/S, Paris, France

PND22	COST-EFFECTIVENESS OF DONEPEZIL IN ALZHEIMER'S DISEASE IN SWEDEN
	Mesterton J¹, By Å², Sandelin R², Jönsson L¹ ¹i3 Innovus, Stockholm, Sweden, ²Pfizer AB, Sollentuna, Sweden

PND23	HEALTH ECONOMIC EVALUATION OF LAMOTRIGINE VERSUS LEVETIRACETAME IN THE INITIAL MONOTHERAPY OF EPILEPSY (LALIMO-TRIAL)
	Balzer-Geldsetzer M, Reese JP, Rosenow F, Strzelczyk A, Hamer HM, Dodel R Philipps University, Marburg, Germany

PND24	TREATMENT OF ADVANCED PARKINSON'S DISEASE IN THE UNITED STATES: A COST-UTILITY MODEL
	Tarrants ML¹, Groenendaal H², Armand C³ ¹Teva Neuroscience, Kansas City, MO, USA, ²Vose Consulting, Boulder, CO, USA, ³H. Lundbeck A/S, Paris, France

PND25	COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY
	Toumi M¹, Lamure M¹, Grishchenko M², Cochran J², Rive B¹ ¹University Claude Bernard Lyon I, Villeurbanne Cedex, France, ²Lundbeck SAS, Paris, France

PND26	COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS IN SPAIN
	Arbizu T¹, Piñol C², Casado V³ ¹Hospital de Bellvitge, Hospitalet de Llobergat, Barcelona, Spain, ²Bayer HealthCare, Barcelona, Spain, ³Hospital de Bellvitge, Hospitalet del LLobregat, Barcelona, Spain

PND27	A DISCRETE EVENT SIMULATION OF PREGABALIN COMPARED TO USUAL CARE IN REFRACTORY NEUROPATHIC PAIN
	Lister S¹, Gordon JP², McEwan P² ¹Pfizer Limited, Tadworth, Surrey, UK, ²CHKS Health Economics Unit, Cardiff, UK

PND28	ADHERENCE AS A PREDICTOR OF THE UTILIZATION OF HEALTH CARE RESOURCES IN A MULTIPLE SCLEROSIS POPULATION USING INTERFERONS
	Faris R¹, Steinberg S¹, Chang CF², Tang J¹, Tankersley MA¹ ¹Accredo Health Group, Memphis, TN, USA, ²University of Memphis, Memphis, TN, USA

NEUROLOGICAL DISORDERSPatient-Reported Outcomes Studies
PND29	PARKINSON'S DISEASE DRUG THERAPIES: MEDICATION COMPLIANCE AND PERSISTENCE
	Tarrants ML¹, Denarie MF², Karabas T¹, Castelli-Haley J¹, Millard J², Zhang D² ¹Teva Neuroscience, Kansas City, MO, USA, ²IMS Health, Plymouth Meeting, PA, USA

PND30	MEDICATION ADHERENCE WITH DISEASE MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS: FINDINGS FROM A US NATIONAL DATABASE OF EMPLOYEES
	Brook RA¹, Rajagopalan K², Kleinman NL³, Beren IA⁴ ¹The JeSTARx Group, Newfoundland, NJ, USA, ²Biogen Idec Pharmaceuticals, Cambridge, MA, USA, ³HCMS Group, Paso Robles, CA, USA, ⁴HCMS Group, Cheyenne, WY, USA

PND31	HEALTH UTILITY SCORES ASSOCIATED WITH A HYPOTHETICAL MODERATE ALZHEIMER'S DISEASE HEALTH STATE: A CANADIAN SURVEY OF THE GENERAL PUBLIC
	Tarride JE, Oremus M, Clayton N, Raina P McMaster University, Hamilton, ON, Canada

PND32	NEW QUALITY OF LIFE (QOL) DATA ON UK PATIENTS WITH REFRACTORY NEUROPATHIC PAIN
	Lister S¹, Gordon JP², McEwan P² ¹Pfizer Limited, Tadworth, Surrey, UK, ²CHKS Health Economics Unit, Cardiff, UK

PND33	LINGUISTIC VALIDATION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29) FOR USE IN 29 LANGUAGES
	Osmani D¹, Rajagopalan K², Hobart J³ ¹MAPI Institute, Lyon, France, ²Biogen Idec, WELLESLEY, MA, USA, ³Peninsula College of Medicine & Dentistry, Plymouth, UK

PND34	REVIEW OF PATIENT-REPORTED OUTCOME MEASURES FOR DAYTIME FUNCTIONING
	Choi JC¹, Joish VN², Suh DC¹ ¹Rutgers University, Piscataway, NJ, USA, ²Sanofi-aventis, Bridgewater, NJ, USA

PND35	FACTORS DRIVING PATIENT SELECTION OF PRIMARY MEDICATION FOR MULTIPLE SCLEROSIS
	Jeffery D¹, Kirzinger S², Halper J³, Preblick R⁴, Bi YJ⁴, Suarez G⁵, Jo H⁶, Bharmal M⁶ ¹Wake Forest University School of Medicine, Winston-Salem, NC, USA, ²University of Louisville, Louisville, KY, USA, ³MS Center at HNH, Teaneck, NJ, USA, ⁴Bayer HealthCare Pharmaceuticals, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, USA, ⁵Bayer HealthCare Pharmaceuticals, Inc., US Medical Affairs, Wayne, NJ, USA, ⁶Quintiles, Inc., Falls Church, VA, USA

PND36	HEALTH-RELATED QUALITY OF LIFE, EDSS AND TIMED 25-FOOT WALK IN A MULTIPLE SCLEROSIS POPULATION OF A REAL-WORLD OBSERVATIONAL OUTCOMES STUDY: BASELINE DATA FROM ROBUST
	Jeffery D¹, Kirzinger S², Halper J³, Preblick R⁴, Bi YJ⁴, Gemmen EK⁵ ¹Wake Forest University School of Medicine, Winston-Salem, NC, USA, ²University of Louisville, Louisville, KY, USA, ³MS Center at HNH, Teaneck, NJ, USA, ⁴Bayer HealthCare Pharmaceuticals, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, USA, ⁵Quintiles, Inc, Falls Church, VA, USA

PND37	RESPONSIVENESS AND CLINICAL IMPORTANT DIFFERENCES OF THE FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS: RESULTS OF A LARGE MULTINATIONAL OBSERVATION STUDY
	Günther OH¹, Miltenburger C², Pozzilli C³, Oentrich W⁴ ¹i3 Innovus Berlin, Berlin, Germany, ²i3 Innovus, Berlin, Germany, ³University of Rome La Sapienza, Rome, Italy, ⁴Bayer Schering Pharma AG, Berlin, Germany

PND38	COSTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GILLES DE LA TOURETTE'S SYNDROME
	Balzer-Geldsetzer M¹, Müller-Vahl K², Dodel I¹, Reese JP¹, Oertel WH¹, Dodel R¹ ¹Philipps University, Marburg, Germany, ²Hannover Medical School, Hannover, Germany

PND39	IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS ON NATALIZUMAB IN THE UNITED STATES
	Agarwal S¹, Stephenson JJ², Hou L², Kamat S², Rajagopalan K³ ¹Biogen Idec Pharmaceuticals, Wellesley, MA, USA, ²HealthCore, Inc., Wilmington, DE, USA, ³Biogen Idec Pharmaceuticals, Cambridge, MA, USA

PND40	PATIENT REPORTED OUTCOMES IN THE EARLY STAGES OF MULTIPLE SCLEROSIS: THE BEGIN STUDY
	Hagströmer M¹, Sjostrom M¹, Hoebel N², Wicklein EM³, Merito M², Tintoré M⁴ ¹Karolinska Institutet, Stockholm, Sweden, ²Kendle GmbH, Munich, Germany, ³Bayer Schering Pharma AG, Berlin, Germany, ⁴University of Barcelona Hospital Vall d`Hebron, Barcelona, Spain

PND41	IMPROVEMENT IN PATIENT SATISFACTION WITH INCREASING NATALIZUMAB TREATMENT DURATION IN MULTIPLE SCLEROSIS PATIENTS IN THE UNITED STATES
	Stephenson JJ¹, Hou L², Agarwal S³, Rajagopalan K⁴, Kamat S² ¹HealthCore, Inc, Wilmington, DE, USA, ²HealthCore, Inc., Wilmington, DE, USA, ³Biogen Idec Pharmaceuticals, Wellesley, MA, USA, ⁴Biogen Idec Pharmaceuticals, Cambridge, MA, USA

PND42	INTERPRETING SCORES ON THE MULTIPLE SCLEROSIS-SPECIFIC PRIMUS AND U-FIS OUTCOME MEASURES
	Twiss J¹, Doward LC¹, McKenna SP¹, Eckert B² ¹Galen Research, Manchester, UK, ²Novartis Pharma AG, Basel, Switzerland

PND43	ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE AND RELAPSE IN THE PREVIOUS YEAR AMONG MULTIPLE SCLEROSIS PATIENTS: BASELINE DATA FROM ROBUST
	Halper J¹, Jeffery D², Kirzinger S³, Preblick R⁴, Bi YJ⁴, Gemmen EK⁵ ¹MS Center at HNH, Teaneck, NJ, USA, ²Wake Forest University School of Medicine, Winston-Salem, NC, USA, ³University of Louisville, Louisville, KY, USA, ⁴Bayer HealthCare Pharmaceuticals, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, USA, ⁵Quintiles, Inc, Falls Church, VA, USA

PND44	EVALUATION OF THE IMPACT OF PARKINSON'S DISEASE SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE. PD-QOL STUDY
	Balañá M¹, Martinez-Martin P², Hernandez B³ ¹Novartis Pharmaceuticals, Barcelona, Spain, ²Institute of Health Carlos III, Madrid, Spain, ³Novartis Farmacéutica, S.A.., Barcelona, Spain

NEUROLOGICAL DISORDERSHealth Care Use & Policy Studies
PND45	PROLONGED-RELEASE MELATONIN: REAL-LIFE EVIDENCE FROM A GERMAN LONGITUDINAL PRESCRIPTION DATABASE
	Angermeyer MC¹, Bineau S², Maman K², Toumi M³, Milea D² ¹University of Leipzig, Leipzig, Saxony, Germany, ²Lundbeck SAS, Paris, France, ³University Claude Bernard Lyon I, Villeurbanne Cedex, France

PND46	A SYSTEMATIC REVIEW AND META-ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF CIDP
	Gaebel K¹, Blackhouse G¹, Campbell K¹, Robertson D¹, Xie F¹, Assasi N¹, Chalk C², Levine M¹, Goeree R¹ ¹McMaster University, Hamilton, ON, Canada, ²McGill University, Montreal, QC, Canada

PND47	ASSESSING CANADIANS' WILLINGNESS-TO-PAY FOR ALZHEIMER'S DISEASE MEDICATIONS
	Oremus M, Tarride JE, Raina P, Clayton N McMaster University, Hamilton, ON, Canada

PND48	SUPPORT FOR PROVIDING UNRESTRICTED ACCESS TO AN ALZHEIMER'S DISEASE MEDICATION IN CANADA: RESULTS FROM A STUDY OF THE GENERAL POPULATION
	Clayton N, Oremus M, Tarride JE, Raina P McMaster University, Hamilton, ON, Canada

PND49	MIGRAINE: PRESCRIBING PATTERNS IN A SOUTH AFRICAN PRIMARY CARE PATIENT POPULATION
	Truter I Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa

POSTER PRESENTATIONS SESSION II
SET-UP:	Monday, 26 October, 7:30 – 8:00
POSTER DISPLAY HOURS:	Monday, 26 October, 8:00 – 19:00
POSTER AUTHOR DISCUSSION HOUR:	Monday, 26 October, 17:30 – 18:30
DISMANTLE:	Monday, 26 October, 19:00 – 19:30

SYSTEMIC DISORDERS/CONDITIONSClinical Outcome Studies
PSY1	SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF PHARMACOTHERAPIES USED IN CHRONIC LOW BACK PAIN
	Aguiar-Ibáñez R¹, Gauthier A², Umuhire D³, Johnston JA⁴, Zhao Y⁴, Le TK⁴ ¹i3 Innovus, Uxbridge, Middlesex, UK, ²Amaris, London, Middlesex, UK, ³i3 Innovus, Nanterre, France, ⁴Eli Lilly and Company, Indianapolis, IN, USA

PSY2	EVALUATING ADVERSE EVENT RISK WITH PROPOXYPHENE: ARE THERE DIFFERENCES BETWEEN ELDERLY VERSUS YOUNGER PATIENTS?
	Bharmal M¹, Garvert W², Jo H², Gemmen EK¹, Hall JR³ ¹Quintiles, Inc, Falls Church, VA, USA, ²Quintiles, Inc., Falls Church, VA, USA, ³Quintiles, Inc., Bracknell, UK

PSY3	DETERMINING THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES FROM A COMMERCIAL CLAIMS DATABASE
	Padula WV, Nair KV University of Colorado at Denver and the Health Sciences Center, Aurora, CO, USA

PSY4	CHALLENGES IN USING THE LITERATURE TO ESTIMATE THE OUTCOMES OF CURRENT RISK STRATIFICATION METHODS IN ADULT PATIENTS WITH PRIMARY ACUTE MYELOID LEUKEMIA
	Leunis A, Redekop WK, Uyl-de Groot CA, Lowenberg B Erasmus MC, Rotterdam, The The Netherlands

PSY5	WITHDRAWN

PSY6	EFFECT OF MODERATE-INTENSITY EXERCISE TRAINING AND DIET ON BODY COMPOSITION AND EXERCISE CAPACITY IN OBESE CHILDREN
	Tóth-Steinhausz V¹, Gombocz K², Lemle Z², Stahl P², Ferenczi A², Bogáné Fatér Z¹, Balog E¹, Császárné Gombos G¹, Kriszbacher I³, Schmidt B¹ ¹University of Pécs, Zalaegerszeg, Hungary, ²Zala County Hospital, Zalaegerszeg, Hungary, ³University of Pécs, Pécs, Hungary

PSY7	EVALUATION OF MEASURES UNDERTAKEN TO ENHANCE THE ROBUSTNESS OF THE FABRY OUTCOME SURVEY (FOS)
	Clarke J¹, Beck M², Giugliani R³, Sunder-Plassmann G⁴, Elliott P⁵, Hernberg-Stahl E⁶, Pintos-Morell G⁷ ¹Hospital for Sick Children, Toronto, Ontario, Canada, ²University of Mainz, Mainz, Germany, ³Hospital de Clinicas/UFRGS, Porto Alegre, RS, Brazil, ⁴Medical University Vienna, Vienna, Austria, ⁵Heart Hospital, London, UK, ⁶Shire HGT AB, Danderyd, Sweden, ⁷University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain

PSY8	TAPENTADOL EXTENDED RELEASE (ER) FOR CHRONIC LOW BACK PAIN: RESULTS OF EUROQOL-5 DIMENSION (EQ-5D) AND SHORT FORM-36 (SF-36) HEALTH STATUS QUESTIONNAIRES
	Kavanagh S¹, Lange B², Ashworth J², Etropolski MS³, McNeill M³, Rauschkolb C³ ¹Johnson & Johnson Pharmaceutical Services, Beerse, Belgium, ²Grünenthal GmbH, Aachen, Germany, ³Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA

PSY9	ADHERENCE TO DULOXETINE THERAPY AND HEALTH CARE COSTS AMONG PATIENTS WITH FIBROMYALGIA
	Chen SY¹, Boulanger L¹, Fraser K¹, Wu N¹, Zhao Y² ¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PSY10	TREATING FIBROMYALGIA WITH DULOXETINE: WHAT IS THE ASSOCIATION BETWEEN AVERAGE DAILY DOSE, MEDICATION ADHERENCE, AND HEALTHCARE COSTS?
	Wu N¹, Chen SY¹, Fraser K¹, Boulanger L¹, Zhao Y² ¹Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

PSY11	DEFI (DETERMINATION OF EPIDEMIOLOGY OF FIBROMYALGIA) A FRENCH PREVALENCE STUDY OF FIBROMYALGIA
	Kosa M¹, Ravaud P², Perrot S³, Vicaut E⁴, Servant D⁵, Pichot L¹ ¹PFIZER FRANCE, Paris, France, ²Groupe hospitalier Bichat, Paris, France, ³Hôpital Hôtel Dieu, Paris, France, ⁴Hôpital Fernand Widal, Paris, France, ⁵Clinique Fontan, Lille, France

SYSTEMIC DISORDERS/CONDITIONSCost Studies
PSY12	ECONOMIC AND CLINICAL EFFICACY BENEFITS OF THE USE OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
	Xaplanteris L¹, Papanicolaou S² ¹Janssen Cilag Greece, Athens, Greece, ²PRMA Consulting Ltd, Hampshire, UK

PSY13	REIMBURSEMENT OF FOODS FOR SPECIAL MEDICAL PURPOSES PRODUCTS FOR PHENYLKETONURIA IN POLAND: A BUDGET IMPACT ANALYSIS
	Rys P, Marcisz A, Palka I, Plisko R, Wladysiuk M HTA Consulting, Krakow, Poland

PSY14	COST-EFFECTIVENESS AND BUDGET IMPACT OF LOW DOSE 7-DAY BUPRENORPHINE PATCH FOR MODERATE TO SEVERE OSTEOARTHRITIS PAIN IN THE CONTEXT OF KOREA NATIONAL HEALTH INSURANCE
	Lim EA, Park JA, An YJ, Goo DH, Choi SE Seoul National University, Seoul, South Korea

PSY15	A COMPARATIVE OUTCOMES ANALYSIS OF DIFFERENT BARIATRIC SURGERIES
	Hayward A¹, Purdy C¹, Alverio M¹, Magar RS² ¹AHRM Inc., Buffalo, NY, USA, ²AHRM Inc., Raleigh, NC, USA

PSY16	THE DIRECT AND INDIRECT COSTS OF THE ANKYLOSING SPONDYLITIS IN THE CZECH REPUBLIC - COMPARISON BETWEEN 2005 AND 2008 STUDIES
	Petrikova A¹, Dolezal T², Skoupá J³ ¹University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic, ²Charles University, Prague, Czech Republic, ³Pharma Projects, Prague, Czech Republic

PSY17	COSTS OF FIBROMYALGIA: RESULTS FROM A CROSS-SECTIONAL STUDY IN GERMANY
	Winkelmann A¹, Schaefer C², Ryan K³, Chandran AB⁴, Zlateva G⁵, Lenz C⁶ ¹University Hospital Munich, Munchen, Germany, ²Covance Market Access, Gaithersburg, MD, USA, ³Covance Market Access Services, Gaithersburg, MD, USA, ⁴Pfizer, Inc, New York, NY, USA, ⁵Pfizer Inc, New York, NY, USA, ⁶Pfizer Pharma GmbH, Karlsruhe, Germany

PSY18	THE BURDEN OF OBESITY IN ONTARIO
	Tarride JE, Haq M, O'Reilly D, Xie F, Blackhouse G, Bowen JM, Goeree RA McMaster University, Hamilton, ON, Canada

PSY19	DIRECT AND INDIRECT COSTS FOR PATIENTS WITH OPIOID INDUCED CONSTIPATION (OIC) AFTER TREATMENT WITH STRONG OPIOIDS IN SWEDEN
	Hjalte F¹, Hjortsberg C¹, Berggren AC², Bergendahl H³ ¹The Swedish Institute for Health Economics, IHE, Lund, Sweden, ²Mundipharma AB, Göteborg, Sweden, ³The Karolinska University Hospital, Stockholm, Sweden

PSY20	COSTS AND COST DRIVERS OF IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA AND INHIBITORS
	Bojke C¹, Botteman MF², Wilke CT³, Stephens JM², Kroner B⁴ ¹Pharmerit International, Fishergate, York, UK, ²PharMerit North America LLC, Bethesda, MD, USA, ³University of Illinois at Chicago, Chicago, IL, USA, ⁴RTI International, Rockville, MD, USA

PSY21	COST STUDY OF HAEMOPHILIA IN MOROCCO
	Plun-Favreau J¹, By Z², Lindner L³, Prior M³ ¹Novo Nordisk Pharma S.A.S., Zurich Oerlikon, Switzerland, ²Novo Nordisk Pharma S.A.S., Casablanca, Morocco, ³IMS Health, Barcelona, Spain

PSY22	COST OF OBESITY TREATMENT IN POLAND
	Macioch T¹, Perkowski P¹, Jarosz A², Hermanowski T¹ ¹Medical University of Warsaw, Warsaw, Poland, ²National Food and Nutrition Institute, Warsaw, Poland

PSY23	COST OF FIRST LINE TREATMENT OF NON-HODGKIN'S LYMPHOMA AT PRIVATE HOSPITAL EN MEXICO
	Gomez E¹, Vargas J², Martínez J³, Paladio Á⁴ ¹Centro Médico American British Cowdray, Mexico, DF, Mexico, ²Econopharma Consulting SA de CV, Mexico, DF, Mexico, ³Econopharma, México D.F., Mexico, ⁴Econopharma Consulting SA de CV, Mexico City, Mexico

PSY24	A COST CONSEQUENCE EVALUATION OF TWO MODELS OF CARE OF OUTPATIENTS WITH CHRONIC NEUROPATHIC PAIN IN NEUROLOGY SETTINGS IN SPAIN: GENERAL CLINICS VERSUS SPECIALIZED PAIN CLINICS
	Matías-Guiu J¹, Guerrero M², López-Trigo J³, Montero J⁴, Ortega A⁵, Rejas J⁶ ¹Hospital Clinico Universitario San Carlos, Madrid, Spain, ²Universidad Católica de Murcia, Murcia, Spain, ³Hospital General Universitario de Valencia, Valencia, Spain, ⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Hospital Virgen de las Nieves, Granada, Spain, ⁶Pfizer Spain, Madrid, Spain

PSY25	RENAL ANEMIA (RA) TREATMENT IN MEXICAN PUBLIC HEALTH CARE INSTITUTIONS: AN EVALUATION OF THE COSTS AND CONSEQUENCES
	Gonzalez P¹, Gomez E², Vargas J³ ¹Clínica 196, Instituto Mexicano del Seguro Social, Mexico, Mexico, ²Centro Médico American British Cowdray, Mexico, DF, Mexico, ³Econopharma Consulting SA de CV, Mexico, DF, Mexico

PSY26	ECONOMIC EVALUATION OF THE ADDITION OF RITUXIMAB TO CVP FOR ADVANCED FOLLICULAR LYMPHOMA IN ROMANIA
	Lupu AR¹, Radu PC², Ray JA³, Kalfás CS⁴ ¹Carol Davilla University of Medicine, Bucharest, Romania, ²Panmedica SRL, Craiova, Romania, ³F.Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Roche Romania, Bucharest, Romania

PSY27	COST-EFFECTIVENESS OF ANTIGUNGAL PROPHYLAXIS WITH POSACONAZOLE VERSUS STANDARD AZOLE THERAPY IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS AMONG HIGH RISK HAEMATOLOGY PATIENTS IN CZECH REPUBLIC
	Suchankova E¹, Dolezal T², Simonova J³ ¹Charles University, Prague , Czech Republic, ²Charles University, Praha, Czech Republic, ³Schering-Plough, Prague, Czech Republic

PSY28	IRON DEFICIENCY IN SWEDEN – TREATMENT OPTIONS, COST-EFFECTIVENESS AND REIMBURSEMENT
	Glenngård AH¹, Borg S¹, Danielson BG², Persson U¹ ¹The Swedish Institute for Health Economics, Lund, Sweden, ²University Hospital, Uppsala, Sweden

PSY29	PHARMACOECONOMIC EVALUATION OF TREATMENT ANEMIA WITH ERYTHROPOIETIC AGENTS IN CHRONIC KIDNEY DISEASE PATIENTS
	Morozov A, Kulikov A, Yagudina RI Moscow Medical Academy, Moscow, Russia

PSY30	COST-UTILITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) COMPARED WITH CORTICOSTEROIDS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IN CANADA
	Blackhouse G¹, Xie F¹, Gaebel K¹, Robertson D¹, Levine M¹, Chalk C², Assasi N¹, Goeree RA¹ ¹McMaster University, Hamilton, ON, Canada, ²McGill University, Montreal, QC, Canada

PSY31	COST-MINIMIZATION ANALYSIS COMPARING 5% AND 10% INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS IN THE TREATMENT OF PRIMARY IMMUNE DEFICIENCY
	Bonnet P¹, Connolly M² ¹Baxter BioScience, Westlake Village, CA, USA, ²Global Market Access Solutions, St Prex, Switzerland

PSY32	THALIDOMIDE PLUS MELPHALAN AND PREDNISONE FOR AUSTRALIAN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA IS COST-EFFECTIVE WHEN COMPARED WITH MELPHALAN AND PREDNISONE ALONE
	De Abreu Lourenco R, Colman S, Lee C Covance Pty Ltd, North Ryde, NSW, Australia

PSY33	A COST-UTILITY ANALYSIS OF IDET COMPARED WITH SPINAL FUSION
	Stamuli E¹, Claxton K², Grevitt MP³, Hegarty J⁴, Righetti C⁵ ¹University of York, York, North Yorkshire, UK, ²University of York, York, UK, ³University Hospitals Nottingham, Nottingham, UK, ⁴Nottingham University Hospitals NHS Trust, Nottingham, UK, ⁵York Health Economics Consortium Ltd, York, UK

PSY34	COST-UTILITY OF BARIATRIC SURGERY IN THE TREATMENT FOR MORBID OBESITY IN FINLAND
	Mäklin S¹, Malmivaara A¹, Victorzon M², Koivukangas V³, Linna M¹, Sintonen H⁴ ¹National Institute for Health and Welfare, Helsinki, Finland, ²Vaasa Central Hospital, Vaasa, Finland, ³Oulu University hospital, Oulu , OYS, Finland, ⁴University of Helsinki AND National Institute of Health and Welfare, Helsinki, Finland

PSY35	PROCESS MEASUREMENT IN IV-PCA AT UPPSALA UNIVERSITY HOSPITAL SWEDEN
	Liwing J¹, Rebmann I², Idänpään-Heikkilä JJ³, Lothgren M¹, Spinelli Scala M¹, Zambrano-Martin S², Marquardt C⁴, Gordh T⁴ ¹Janssen-Cilag AB, Sollentuna, Sweden, ²Siemens AG Healthcare Consulting, Erlangen, Germany, ³Janssen-Cilag Oy, Espoo, Finland, ⁴Akademiska sjukhuset, Uppsala, Sweden

PSY36	CHANGES IN RATES OF SICKLE CELL DISEASE-RELATED INPATIENT STAYS AND ASSOCIATED RESOURCE USE AMONG AFRICAN AMERICANS IN THE UNITED STATES FOLLOWING APPROVAL OF HYDROXYUREA
	Candrilli SD¹, Davis KL¹, Balkrishnan R², O'Brien S³ ¹RTI Health Solutions, Research Triangle Park, NC, USA, ²University of Michigan, Ann Arbor, MI, USA, ³The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA

SYSTEMIC DISORDERS/CONDITIONSPatient-Reported Outcomes Studies
PSY37	IMPACT OF TOLVAPTAN ON SELF-REPORTED UTILITY SCORES IN HYPONATREMIC PATIENTS
	Cyr PL¹, McInnis M¹, Slawsky K¹, Krasa H², Czerwiec F², Ouyang J², Goss TF³, Verbalis JG⁴ ¹Boston Healthcare Associates, Inc., Boston, MA, USA, ²Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA, ³Boston Healthcare Associates, Inc., Washington, DC, USA, ⁴Georgetown Medical Center, Washington, DC, USA

PSY38	ELICITING HEALTH STATE UTILITIES FOR IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA: RESULTS OF A GENERAL PUBLIC BASED TIME TRADE-OFF SURVEY
	Arnold DM¹, Tinmouth A², Iskedjian M³, Gafni A¹, Deuson R⁴, Isitt J⁵, Mikhael J⁶ ¹McMaster University, Hamilton, ON, Canada, ²Department of Medicine, University of Ottawa, Ottawa, ON, Canada, ³PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, ⁴Amgen, Thousand Oaks, CA, USA, ⁵Amgen Inc, Thousand Oaks, CA, USA, ⁶Mayo Clinic Arizona, Scottsdale, AZ, USA

PSY39	UTILITY MEASUREMENT STUDY FOR PATIENTS WITH CONTROLLED AND UNCONTROLLED PHENYLKETONURIA – A CASE STUDY FOR AN ORPHAN DISEASE
	Stamuli E¹, Trueman P¹, Barth JH², Chakrapani A³, D'Souza NA⁴, Galloway PJ⁵, MacDonald A³, Wildgoose JK⁶, Chauhan D⁷ ¹University of York, York, North Yorkshire, UK, ²Leeds General Infirmary, Leeds, Yorkshire, UK, ³Birmingham Children's Hospital, Birmingham, UK, ⁴Princess of Wales Hospital, Bridgend, Wales, UK, ⁵Yorkhill Children's Hospital, Glasgow, UK, ⁶St Lukes Hospital, Bradford, UK, ⁷Merck Serono Ltd, Feltham, Middlesex, UK

PSY40	A COMPARATIVE STUDY ON HEMOPHILIA TREATMENT AND MEDICATION BY THE PRESENCE OF INHIBITORS IN SOUTH KOREA
	Kim JY, Lee EK Sook Myung Women's University, Seoul, South Korea

PSY41	MEASUREMENT OF HEALTH UTILITY VALUES IN THE UNITED KINGDOM FOR HEALTH STATES RELATED TO IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA (ITP)
	Szende A¹, Brazier J², Schaefer C³, Deuson R⁴, Isitt J⁵, Vyas P⁶ ¹Covance Market Access Services, Inc., Leeds, UK, ²University of Sheffield, Sheffield, UK, ³Covance Market Access, Gaithersburg, MD, USA, ⁴Amgen, Thousand Oaks, CA, USA, ⁵Amgen Inc, Thousand Oaks, CA, USA, ⁶Weatherall Institute of Molecular Medicine, Oxford, UK

PSY42	BLEEDING DISORDERS, MENORRHAGIA AND IRON DEFICIENCY: AN EXAMINATION OF QUALITY OF LIFE
	Horsman JR¹, Rae CS², Furlong W², McGugan J², Barr RD², Lillicrap D³ ¹Health Utilities Inc, Dundas, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³Queen's University, Kingston, ON, Canada

PSY43	MAPPING THE ROLAND MORRIS DISABILITY QUESTIONNAIRE FOR BACK PAIN INTO UTILITY INDEX
	Chuang LH, The UK BEAM Trial . York Trials Unit, University of York, York, UK

PSY44	LINGUISTIC VALIDATION OF HAEMOPHILIA-SPECIFIC PATIENT-RATED OUTCOMES (HAEMO-QOL, HAEM-A-QOL, HEMO-SAT) IN UP TO 32 LANGUAGES
	Von Mackensen S¹, Strandberg-Larsen M², Celerier S³ ¹Institute of Medical Psychology, München, Germany, ²Novo Nordisk A/S, Søborg, Denmark, ³MAPI Institute, Lyon, France

PSY45	DEVELOPMENT OF A QUESTIONNAIRE TO EVALUATE TREATMENT SATISFACTION OF PATIENTS WITH SEVERE CROHN'S DISEASE: QUALITATIVE STEPS
	Arnould B¹, Marrel A¹, Marant C¹, Spizak C¹, Colombel JF², Hagege H³, Faure P⁴, Lemann M⁵, Nahon S⁶, Tucat G⁷, Vandromme L⁸, Thibout E⁹, Goldfarb G⁹ ¹Mapi Values, Lyon, France, ²Hôpital Claude Huriez, Lille, France, ³Centre Hospitalier Intercommunal, Créteil, France, ⁴Clinique Saint-Jean du Languedoc, Toulouse, France, ⁵Hôpital Saint Louis, Paris, France, ⁶Centre Hospitalier Intercommunal Le Raincy Montfermeil, Montfermeil, France, ⁷Private doctor, Paris, France, ⁸Private Doctor, Reims, France, ⁹Abbott France SA, Rungis, France

PSY46	HEALTH-RELATED QUALITY OF LIFE BURDEN AMONG FIBROMYALGIA PATIENTS: RESULTS FROM A CROSS-SECTIONAL STUDY IN FRANCE
	Perrot S¹, Schaefer C², Ryan K³, Chandran AB⁴, Zlateva G⁵, Kosa M⁶ ¹Hôpital Hôtel Dieu Paris (France), Paris, France, ²Covance Market Access, Gaithersburg, MD, USA, ³Covance Market Access Services, Gaithersburg, MD, USA, ⁴Pfizer, Inc, New York, NY, USA, ⁵Pfizer Inc, New York, NY, USA, ⁶PFIZER FRANCE, Paris, France

PSY47	VALIDATION OF THE FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY (FACIT) – FATIGUE SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
	Lai JS¹, Beaumont J¹, Cella D¹, Brunetta P², Ogale S² ¹Northwestern University, Chicago, IL, USA, ²Genentech, Inc, South San Francisco, CA, USA

PSY48	INSOMNIA AMONGST PATIENTS WITH CHRONIC PAIN AND INFLUENCE OF ADJUSTMENT OF PAIN MEDICATION IN GERMANY
	Horlemann J¹, Zieglgaensberger W², Kanitscheider C³ ¹German Pain Association, Kevelaer, Germany, ²Max Planck Institute of Psychiatry, Munich, Germany, ³TNS Healthcare GmbH, Munich, Germany

PSY49	VALIDATION OF THE SF-36 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
	Beaumont J¹, Lai JS¹, Cella D¹, Brunetta P², Ogale S² ¹Northwestern University, Chicago, IL, USA, ²Genentech, Inc, South San Francisco, CA, USA

PSY50	THE EFFECT OF OBESITY ON PHYSICAL AND MENTAL HEALTH
	Pappa E¹, Kontodimopoulos N¹, Papadopoulos AA², Tountas Y³, Niakas D¹ ¹Hellenic Open University, Patras, Greece, ²Attikon University Hospital, Athens, Greece, ³University of Athens, Athens, Greece

PSY51	THE IMPACT OF OBESITY ON QUALITY OF LIFE IN POLISH POPULATION
	Macioch T¹, Jarosz A², Golicki D¹, Perkowski P¹, Hermanowski T¹, Krzysiak M³ ¹Medical University of Warsaw, Warsaw, Poland, ²National Food and Nutrition Institute, Warsaw, Poland, ³SPZOZ STOCER, Konstancin-Jeziorna, Poland

PSY52	DEFI A FRENCH PREVALENCE STUDY OF FIBROMYALGIA (FM), HEALTH RELATED QUALITY OF LIFE : SF36
	Servant D¹, Perrot S², Ravaud P³, Vicaut E⁴, Kosa M⁵, Pichot L⁵ ¹Clinique Michel Fontan, Lille, France, ²Hôpital Hôtel Dieu Paris (France), Paris, France, ³Groupe Hospitalier Bichat Paris (France), Paris, France, ⁴Hôpital Fernand Widal Paris (France), Paris, France, ⁵PFIZER FRANCE, Paris, France

PSY53	PELVIC PAIN IN ENDOMETRIOSIS: EFFECT OF PAINKILLERS OR SPORT TO ALLEVIATE SYMPTOMS
	Koppán Á, Hámori J, Vránics I, Garai J, Kriszbacher I, Bódis J, Rébék-Nagy G, Boncz I, Koppán M University of Pécs, Pécs, Hungary

PSY54	COST-EFFECTIVENESS OF ENZYME REPLACEMENT THERAPY FOR GAUCHER'S DISEASE IN THE URAL ADMINISTRATION DISTRICT OF RUSSIA FEDERATION
	Zhukovskaya EV¹, Ustugova AM², Spichak II³, Zub NV⁴ ¹Medical Academy, Chelyabinsk, Russia, ²Health Ministry of Chelyabinsk Region, Chelyabinsk, Russia, ³Regional Children's Hospita, Chelyabinsk, Russia, ⁴Regional Children Hospital, Chelyabinsk, Russia

SYSTEMIC DISORDERS/CONDITIONSHealth Care Use & Policy Studies
PSY55	IMPACT OF THE NEW RECOMMENDATIONS IN THE USE OF PROTHROMBIN COMPLEX CONCENTRATES AND VITAMIN K ANTAGONISTS IN FRANCE: ILLUSTRATION OF THE GUIDELINES RESPECT IN HOSPITAL AND ITS ECONOMIC CONSEQUENCES
	Bernard M, Mimoun G, Arnaud P, Peytavin G Bichat-Claude Bernard hospital, Paris, Ile de france, France

PSY56	SYSTEMATIC REVIEW OF THE DIRECT COSTS RELATED TO OBESITY AND ASSOCIATED DISEASES IN POLAND
	Perkowski P¹, Hermanowski T¹, Macioch T¹, Jarosz A² ¹Medical University of Warsaw, Warsaw, Poland, ²National Food and Nutrition Institute, Warsaw, Poland

PSY57	REIMBURSEMENT OF INNOVATIVE DRUGS IN SLOVAKIA - PHARMACOECONOMICS OF USTEKINUMAB IN PSORIASIS
	Tomek D¹, Bielik J² ¹Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, ²Trencin University, Trencin, Slovak Republic, ³Janssen-Cilag, Bratislava, Slovak Republic

PSY58	RIMONABANT IN CLINICAL PRACTICE (RICP). A SWEDISH MULTICENTER SURVEY IN PRIMARY CARE
	Linder R¹, Olsson Birgersson M², de Faire U³, Ridderstråle M⁴, Rössner S³, Sjöström L⁵, Rydén L³ ¹Pygargus AB, Stockholm, Sweden, ²sanofi aventis AB, Stockholm, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴University Hospital MAS, Malmö, Sweden, ⁵Sahlgrenska University Hospital, Gothenburg, Sweden

PSY59	REVIEW OF RECOMMENDATIONS OF HEALTH TECHNOLOGY ASSESSMENTS ON ORLISTAT AND SIBUTRAMINE
	Jensen RCØ¹, Adalsteinsson E¹, Toumi M², Hemels M¹ ¹Novo Nordisk A/S, Søborg, Denmark, ²University Claude Bernard Lyon I, Villeurbanne Cedex, France